Monoclonal antibodies specific to surface antigens on mesenchymal stem cells and use thereof

Monoclonal antibodies targeting integrin α2, α3, and αV on mesenchymal stem cells address the challenge of isolating hMSCs from diverse tissues, enabling effective differentiation and regenerative therapies for bone and fat regeneration.

KR103045278B1Active Publication Date: 2026-11-06IND ACAD COOP GRP OF SEJONG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020200050359
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-04-24
Publication Date
2026-11-06
Estimated Expiration
2040-04-24

AI Technical Summary

Technical Problem

Current methods fail to isolate human mesenchymal stem cells (hMSCs) that meet minimum criteria from diverse tissue environments using a single surface marker, hindering effective differentiation into osteoblasts and adipocytes for bone and fat regeneration.

Method used

Development of monoclonal antibodies targeting integrin α2, α3, and αV-expressing mesenchymal stem cells, utilizing specific CDR sequences to isolate and differentiate hMSCs into osteocytes and adipocytes.

Benefits of technology

Enables efficient isolation and differentiation of hMSCs, facilitating bone and fat cell analysis and regenerative therapies by specifically identifying cell surface molecules.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112020042722788-PAT00021_ABST
    Figure 112020042722788-PAT00021_ABST
Patent Text Reader

Abstract

The present invention relates to a monoclonal antibody that specifically binds to integrin α2-expressing mesenchymal stem cells or mesenchymal stem cells having osteocytic differentiation ability, a screening composition and a screening kit containing the same, and a method for screening integrin α2-expressing mesenchymal stem cells or mesenchymal stem cells having osteocytic differentiation ability.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a monoclonal antibody that recognizes a surface marker specific to mesenchymal stem cells and its uses. Background Technology

[0003] Human mesenchymal stem cells (hMSCs) can differentiate into multiple lineages of mesenchymal tissue, including osteoblasts (OBs), adipocytes, myocytes, and chondrocytes. While hMSCs can differentiate into various cell types, their differentiation into osteocytes and adipocytes has been extensively studied for successful bone formation and regeneration. Osteocytes constitute approximately 95% of all bone cells in adult bone and differentiate from hMSCs via OBs. Although many researchers have attempted to differentiate hMSCs into OBs and osteocytes for bone formation and regeneration, significant problems have arisen because hMSCs are a heterogeneous population with variable functions, and their characteristics are highly variable depending on the tissue source, subpopulation, and culture conditions. Currently, cloning based on single surface markers cannot isolate cells satisfying minimum hMSC criteria from diverse tissue environments. Therefore, there is no definitive marker to identify and isolate OBs when differentiating into bone lineages from mixed population samples.

[0004] Transforming growth factor-β1 (TGF-β1), bone morphogenetic protein 2 (BMP-2), and Runx-associated transcription factor 2 (Runx2) are considered to be major regulators of OB development during osteogenic formation. TGF-β1 is a representative TGF-β isotype expressed in bone and has been extensively studied during osteogenic formation and remodeling. TGF-β1 signaling is known to expand hMSCs and stimulate early differentiation of OBs, while inhibiting the differentiation of OBs into osteocytes. BMP signaling influences differentiation into OBs, and treatment of hMSCs with BMP-2 promotes osteogenic formation. Treatment of hMSCs with both TGF-β1 and BMP-2 accelerates osteogenic formation through OB proliferation and keeps immature OBs from further differentiation. Runx2 is a major transcription factor for early OB differentiation and osteogenic formation and is controlled by TGF-β1 and BMP-2 during osteogenic formation. Runx2 is also upregulated in TGF-β1-treated cancer cells.

[0005] Epithelial-Mesenchymal Transition (EMT) is considered to play a crucial role in cancer metastasis and recurrence and is induced by cytokines such as TGF-β1. BMP-2, BMP-4, and BMP-7 also promote EMT and invasiveness in pancreatic cancer cells. Runx2 also participates in TGF-β1-induced EMT. Cancer cells with induced EMT exhibit enhanced invasive and metastatic capabilities and show similarities to hMSC-like characteristics. TGF-β1-treated A549 cells well represent EMT-phenotyped cells. To search for novel cell surface markers in EMT-phenotypic-circulating tumor cells, we generated a panel of monoclonal antibodies (MAbs) against surface molecules in TGF-β1-treated A549 non-small cell lung cancer (NSCLC) cells. While EMT plays a major role in tumor invasion and metastasis, it also occurs during bone development. EMT plays a crucial role in the differentiation of enamel-forming ameloblasts. Several studies have also shown that EMT causes epithelial cells to differentiate into hard tissues, such as cementum, in the presence of TGF-β-1. Furthermore, EMT recruits epithelial odontogenic stem cells through interactions with various mesenchymal stem cells to form extra teeth. These results suggest that EMT is an important biochemical pathway for the formation of hard tissues, including bone.

[0006] Therefore, in this study, we hypothesized that surface molecules expressed in EMT-phenotype cells could serve as source molecules for finding novel surface markers in OBs similarly regulated by TGF-β1. To this end, we first generated a MAb panel for TGF-β1-treated A549 cells using a decoy immunization strategy.

[0007] Under these circumstances, there is a need for a technology capable of isolating hMSC cells that meet minimum criteria from various tissue environments using cloning based on a single surface marker derived from existing techniques. Furthermore, to understand the precise mechanisms of bone remodeling in bone tissue, a technology capable of specifically identifying cell surface molecules expressed by osteoblasts is required.

[0008] delete Prior art literature

[65535] ACTA MEDICA LITUANICA. 2012. Vol. 19.No. 2. P. 75-79, “Surface markers distinguishing mesenchymal stem cells from ibroblasts” (2012.06) Biomed Res Int. 2019 Mar 3;2019:6376271. “Characterization of Human Mesenchymal Stem Cells from Different Tissues and Their Membrane Encasement for Prospective Transplantation Therapies” (2019.03) The problem to be solved

[0009] The object of the present invention is to provide a monoclonal antibody against integrin α2-expressing mesenchymal stem cells and its uses.

[0010] The object of the present invention is to provide a monoclonal antibody against mesenchymal stem cells having osteocytic differentiation ability and its uses.

[0011] The object of the present invention is to provide a monoclonal antibody against mesenchymal stem cells having adipocyte differentiation ability and its uses. means of solving the problem

[0013] 1. A heavy chain variable region comprising CDR-H1 composed of the amino acid sequence of SEQ ID NO. 1, CDR-H2 composed of the amino acid sequence of SEQ ID NO. 2, and CDR-H3 composed of the amino acid sequence of SEQ ID NO. 3; and

[0014] A light chain variable region comprising CDR-L1 consisting of the amino acid sequence of SEQ ID NO. 4, CDR-L2 consisting of the amino acid sequence of SEQ ID NO. 5, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO. 6;

[0015] A monoclonal antibody containing

[0016] 2. A composition for selecting mesenchymal stem cells having osteocytic differentiation ability comprising the monoclonal antibody of 1 above.

[0017] 3. A kit for selecting mesenchymal stem cells having osteocytic differentiation ability comprising the composition of 2 above.

[0018] 4. A method for selecting mesenchymal stem cells having osteocytic differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of 2 above.

[0019] 5. A method for selecting mesenchymal stem cells having osteocytic differentiation ability, wherein, in the above 4, the cells among the samples that bind to the antibody are further selected as cells having osteocytic differentiation ability.

[0020] 6. A composition for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the monoclonal antibody of 1 above.

[0021] 7. A kit for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the composition of 6 above.

[0022] 8. A method for selecting mesenchymal stem cells having adipocyte differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of 6 above.

[0023] 9. A method for selecting mesenchymal stem cells having adipocyte differentiation ability, wherein, in the above 8, the cells among the above samples that do not bind to the antibody are further selected as cells having adipocyte differentiation ability.

[0024] 10. A heavy chain variable region comprising CDR-H1 having the amino acid sequence of SEQ ID NO. 7, CDR-H2 having the amino acid sequence of SEQ ID NO. 8, and CDR-H3 having the amino acid sequence of SEQ ID NO. 9; and

[0025] A light chain variable region comprising CDR-L1 consisting of the amino acid sequence of SEQ ID NO. 10, CDR-L2 consisting of the amino acid sequence of SEQ ID NO. 11, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO. 12;

[0026] A monoclonal antibody containing

[0027] 11. A composition for selecting integrin α2-expressing mesenchymal stem cells comprising the monoclonal antibody of 10 above.

[0028] 12. A kit for screening integrin α2-expressing mesenchymal stem cells comprising the composition of 11 above.

[0029] 13. A method for selecting integrin α2-expressing mesenchymal stem cells, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of 11 above.

[0030] 14. A method for selecting integrin α2-expressing mesenchymal stem cells according to 13 above, further comprising the step of selecting cells among the samples that bind to the antibody as integrin α2-expressing mesenchymal stem cells.

[0031] 15. A heavy chain variable region comprising CDR-H1 having the amino acid sequence of SEQ ID NO. 13, CDR-H2 having the amino acid sequence of SEQ ID NO. 14, and CDR-H3 having the amino acid sequence of SEQ ID NO. 15; and

[0032] A light chain variable region comprising CDR-L1 consisting of the amino acid sequence of SEQ ID NO. 16, CDR-L2 consisting of the amino acid sequence of SEQ ID NO. 17, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO. 18;

[0033] A monoclonal antibody containing

[0034] 16. A composition for selecting mesenchymal stem cells having osteocytic differentiation ability comprising the monoclonal antibody of 15 above.

[0035] 17. A kit for selecting mesenchymal stem cells having osteocytic differentiation ability comprising the composition of 16 above.

[0036] 18. A method for selecting mesenchymal stem cells having osteocytic differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of 16 above.

[0037] 19. A method for selecting mesenchymal stem cells having osteocytic differentiation ability, wherein, in the above 18, the cells among the samples that bind to the antibody are further selected as cells having osteocytic differentiation ability.

[0038] 20. A composition for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the monoclonal antibody of 15 above.

[0039] 21. A kit for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the composition of 20 above.

[0040] 22. A method for selecting mesenchymal stem cells having adipocyte differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of 20 above.

[0041] 23. A method for selecting mesenchymal stem cells having adipocyte differentiation ability, wherein, in the above 22, the cells among the samples that do not bind to the antibody are further selected as cells having adipocyte differentiation ability. Effects of the invention

[0043] Through the present invention, a monoclonal antibody that specifically binds to integrin α2-expressing mesenchymal stem cells can be produced.

[0044] Through the present invention, mesenchymal stem cells can be efficiently isolated during the analysis of mesenchymal stem cells and the development of cell therapies.

[0045] Through the present invention, bone cells can be efficiently isolated during bone cell analysis research and the development of bone graft regenerative therapeutic agents.

[0046] Through the present invention, it is possible to efficiently isolate fat cells during the analysis of fat cells and the development of regenerative therapies for fat grafting. Brief explanation of the drawing

[0048] Figure 1 illustrates the EMT phenotype of TGF-β1-treated A549 cells. (A) Morphology of A549 and TGF-β1-treated A549 cells. A549 cells were treated with 5 ng / ml TGF-β1 for 4 days. Scale bar is 200 μm. (B) Expression of EMT markers in TGF-β1-treated A549 cells. TGF-β1-treated A549 cells were analyzed by Western blot using the indicated antibody. (C) Cell surface expression of EMT markers in TGF-β1-treated A549 cells. TGF-β1-treated A549 cells were analyzed by flow cytometry using the indicated antibody. The red-colored histogram represents the homozygous control. Figure 2 shows the selection of hybridoma clones specific to EMT-phenotype A549 cells. MAb antigen expression was analyzed in A549 and TGF-β1-treated A549 cells by flow cytometry using the labeled MAb. The expression of E-cadherin (E-cad) and N-cadherin (N-cad) was used as controls. The red-colored histogram represents the homologous controls. Figure 3 shows the results of the analysis of cell surface expression of selected MAb target antigens in osteogenic mesenchymal stem cells and osteoprogenitor cells. Cell surface expression of selected MAb target antigens was investigated by flow cytometry with MAb in two human osteoprogenitor cell lines (hMSC and hFOB) and two human osteoblast cancer cell lines (U2OS and SAOS-2). In addition, the binding of three selected antibodies to human peripheral blood mononuclear cells (PBMCs) was analyzed. The red-filled histogram represents the allotypical control. Figure 4 shows the results of the analysis of changes in the expression of selected MAb target antigens during hMSC osteogenic differentiation. (A) Alizarin Red S staining of hMSCs stimulated with Osteogenic Differentiation Medium (ODM). hMSCs were cultured in ODM for 12 days, and calcium deposition and bone nodules were visualized in red after staining the cells with Alizarin Red S. The scale bar is 200 μm. (B, C) Analysis of RUNX2 knockdown efficiency in U2OS. After transfection with control siRNA or RUNX2 siRNA, the expression of the RUNX2 gene was evaluated by RT-PCR (left panel) and Western blot (right panel). GAPDH or β-actin were used as loading controls. (D) hMSCs treated with TGF-β1 and BMP2 or Osteogenic Differentiation Medium (ODM) were analyzed by flow cytometry using MR14-E5, ER7-A7, and MR1-B1. RUNX2 knockdown U2OS cells were also analyzed by flow cytometry using the same MAb. The red-colored histogram represents the homologous controls. Figure 5 shows the results of identifying cell surface molecules recognized by the selected MAb. A549 cell lysates were immunoprecipitated with the MAb that appeared after biotinylation of the cell surface. After the proteins bound to the beads were eluted, the proteins were detected by Western blot using streptoavidin-horse carrot peroxidase (SA-HRP). Protein G agarose beads were pretreated and used as a control. Figure 6 shows the mass spectrometry identification results of the MR14-E5 antigen after immunoprecipitation by MR14-E5. The peptide obtained by trypsin treatment of the approximately 150 kDa band of A549 cell lysate was analyzed by mass spectrometry. Ten trypsin peptides (underlined) derived from the 150 kDa protein matched the integrin α2 precursor. Figure 7 shows the identification results of the ER7-A7 antigen by mass spectrometry after immunoprecipitation with ER7-A7. The peptide obtained by trypsin treatment of the approximately 130 kDa band of A549 cell lysate was analyzed by mass spectrometry. Five trypsin peptides (underlined) derived from the 130 kDa protein matched the integrin α3 preproprotein. Figure 8 shows the identification results of the MR1-B1 antigen by mass spectrometry after immunoprecipitation with MR1-B1. The peptide obtained by trypsin treatment of the approximately 130 kDa band of A549 cell lysate was analyzed by mass spectrometry. Five trypsin peptides (underlined) derived from the 130 kDa protein matched the integrin αV isoform 1 preproprotein. Figure 9 shows the verification results of cell surface molecules recognized by the selected MAb. (A) Overexpression and immunoprecipitation of integrin α2 (ITGA2) by MR14-E5 anti-His or anti-ITGA2 antibodies. Cell lysates from HEK293T cells transfected with pcDNA3.1+ (control vector) or pCMV-His-ITGA2 expression plasmid were immunoprecipitated with MR14-E5, anti-His, or anti-ITGA2 antibodies. Immunoprecipitates were analyzed by Western blot using anti-ITGA2 or anti-His antibodies. (B) Overexpression and immunoprecipitation of integrin α3 (ITGA3) by ER7-A7, anti-His, or anti-ITGA3 antibodies. Cell lysates of HEK293T cells transfected with pcDNA3.1+ (control vector) or pCMV-FLAG-ITGA3 expression plasmids were immunoprecipitated with ER7-A7, ER7-A7, anti-FLAG, or anti-ITGA3 antibodies. The immunoprecipitated material was analyzed by Western blotting using anti-ITGA3 or anti-FLAG antibodies. (C) Overexpression of integrin αV (ITGAV) and immunoprecipitation by MR1-B1, anti-FLAG, or anti-ITGAV antibodies. Cell lysates of HEK293T cells transfected with pcDNA3.1+ (control vector) or pCMV-FLAG-ITGAV expression plasmids were immunoprecipitated with MR1-B1, anti-FLAG, or anti-ITGAV antibodies. The immunoprecipitated material was analyzed by Western blotting using anti-ITGAV or anti-FLAG antibodies. Protein G agarose beads were pretreated and used as a control. Figure 10 shows the results of the analysis of changes in the expression of integrins αV, α2, α3, and osteocytogenic markers during the differentiation of hMSCs. (A) Alizarin Red S staining of OB in differentiated hMSCs. hMSCs were incubated with ODM for 21 days. To inhibit TGF-β1 signaling derived from the culture medium, SB431542 was added to the ODM (SB o) or not added (SB x) after 7 days of osteocytogenic differentiation. Osteogenesis was indicated by visualizing calcium deposition in red after the cells were stained with Alizarin Red S. (B) Shows changes in the expression of integrins and osteocytogenic markers during the osteocytogenic differentiation of hMSCs. Integrins (ITGAV, ITGA2, ITGA3), osteocytogenic markers (RUNX2, OSX, COL1A1), osteocytogenic common markers (ALP), and adipogenesis markers (C / EBPA) were analyzed in osteocytes of A by quantitative RT-PCR. The values ​​represent the gene expression of differentiated hMSCs on the indicated day compared to hMSCs on day 0 (2 -ΔΔCT (C) Analysis of changes in expression of integrins and hMSC / osteoblast surface markers during osteogenic differentiation of hMSCs. Integrins (integrin α2 / MR14-E5, integrin α3 / ER7-A7, and integrin αV / MR1-B1) and hMSC / osteoblast surface markers (CD73, CD90, CD146, and CD164) were analyzed in osteoblasts of A by flow cytometry. Values ​​are plotted as the relative mean fluorescence intensity (MFI) of hMSCs differentiated from ODM at the indicated dates compared to hMSCs cultured in normal culture medium. **, p <0.01; ***, p <0.005; ns, not significant. Figure 11 shows the changes in expression of integrins αV, α2, α3, and osteoblast and adipogenic markers during the adipogenic differentiation of hMSCs. (A) Oil Red O staining of adipocytes in differentiated hMSCs. hMSCs were incubated with ADM (Adipogenic Differentiation Medium) for 21 days. After staining the cells with Oil Red O, lipid content was visualized in red. (B) Analysis of changes in expression of integrins and hMSC / osteoblast surface markers during the adipogenic differentiation of hMSCs. Integrins (integrin α2 / MR14-E5, integrin α3 / ER7-A7, and integrin αV / MR1-B1) and hMSC / osteoblast surface markers (CD73, CD90, CD146, and CD164) were analyzed in the adipogenic cells of A by flow cytometry. Values ​​were plotted as the relative mean fluorescence intensity (MFI) in differentiated hMSCs at the indicated day by comparing hMSCs in normal medium and ADM differentiation-inducing medium. **, p <0.01; ***, p <0.005. Figure 12 illustrates that MR1-B1-positive hMSCs have a greater potential for osteocytogenesis than MR1-B1-negative hMSCs. (A) Flow cytometry analysis of hMSCs using MR1-B1, anti-CD73, anti-CD90, anti-CD146, and anti-CD164 antibodies after cell isolation using MR1-B1 antibody-based magnetic beads. (B) Alizarin Red S staining of OB in MR1-B1-positive and negative hMSCs after 21 days of culture in ODM. To inhibit TGF-β1 signaling derived from the culture medium, SB431542 was added to ODM after 7 days of osteogenic differentiation. Osteogenesis after osteogenic differentiation of hMSCs was confirmed by Alizarin Red S staining. (CG) qPCR analysis of changes in osteocytogenesis and adipogenesis marker expression during osteocytogenesis in hMSCs. Osteogenesis markers (RUNX2, OSX, COL1A1), osteo / adipocyte common markers (ALP), and adipogenesis markers (C / EBPA) were analyzed in MR1-B1 positive (+) and negative (-) hMSCs at osteogenic differentiation induction periods of 0, 7, 14, and 21, respectively. Values ​​determined by quantitative RT-PCR were the gene expression of differentiated hMSCs on the indicated days compared to MR1-B1 (+) hMSCs on day 0 (2 -ΔΔCT It was expressed as the average multiple change of ). **, p <0.01; ***, p <0.005; ns, not significant. Figure 13 illustrates that MR1-B1 negative hMSCs express higher levels of adipogenesis markers than MR1-B1 positive hMSCs. (AE) In Figure 12, after separating hMSCs into MR1-B1 positive and negative cells using MR1-B1 antibody-based magnetic beads, changes in osteocytic and adipogenesis marker expression during hMSC adipogenesis were analyzed by qPCR. Osteogenesis markers (RUNX2, OSX, COL1A1), osteocytic / adipocyte common markers (ALP), and adipogenesis markers (C / EBPA) were analyzed for MR1-B1 positive ( The values ​​were analyzed at days 0, 7, 14, and 21, respectively, for the induction of adipogenesis differentiation in ) and negative (-) hMSCs. By quantitative RT-PCR, the values ​​for MR1-B1 on day 0 ( ) Gene expression of hMSCs differentiated on the indicated day compared to hMSCs (2 -ΔΔCT It was expressed as the average multiple change of ). Figure 14 shows changes in integrin αV expression during osteocytic differentiation of MR1-B1 negative hMSCs. (A) Flow cytometry analysis of MR1-B1 positive (+) and negative (-) hMSCs induced by MR1-B1 after MR1-B1-based magnetic cell sorting. hMSCs were cultured in ODM for 21 days after MR1-B1-based magnetic cell sorting, and then analyzed by flow cytometry at days 14 and 21. To inhibit TGF-β1 signaling derived from the culture medium, SB431542 was added to ODM after 7 days of osteocytic differentiation. (B) Statistical analysis of A. Values ​​are plotted as the relative mean fluorescence intensity (MFI) of isolated hMSCs at the indicated days, comparing hMSCs cultured in normal medium and ODM differentiation induction medium. **, p < 0.01; ***, p < 0.005. Figure 15 illustrates the potential for greater osteocytosis in ER7-A7 positive hMSCs compared to ER7-A7 negative hMSCs. (A) Flow cytometry analysis of hMSCs using ER7-A7 antibodies after cell isolation with ER7-A7 antibody-based magnetic beads. ER7-A7 positive in hMSCs ( ) and voice ( It can be seen that it is sorted by ). qPCR analysis of changes in expression of osteocytosis and adipogenesis markers during osteocytosis induction in (BF) hMSCs. To inhibit TGF-β1 signaling derived from the culture medium, SB431542 was added to the ODM after 7 days of osteocytotic differentiation. Osteogenesis markers (RUNX2, OSX, COL1A1), osteocytosis common marker (ALP), and adipogenesis marker (C / EBPA) were ER7-A7 positive ( ) and voice( ) The values ​​were analyzed at osteocytogenic differentiation induction periods of 0, 7, 14, and 21 days, respectively, in hMSCs. By quantitative RT-PCR, the values ​​for ER7-A7 on day 0 ( ) Gene expression of hMSCs differentiated on the indicated day compared to hMSCs (2 -ΔΔCT It was displayed as the average multiple change of ). The graph value used was the average value after 2 repetitions. Figure 16 shows that ER7-A7 negative hMSCs express higher adipogenesis markers than ER7-A7 positive hMSCs. (AE) hMSC cells positive ( After separating into ) and negative (-) groups, changes in the expression of osteocytes and adipocyte formation markers were analyzed by qPCR during the induction of adipocyte formation. Osteocyte formation markers (RUNX2, OSX, COL1A1), osteocytes / adipocyte common markers (ALP), and adipocyte formation markers (C / EBPA) were ER7-A7 positive ( ) and negative (-) hMSCs were analyzed at adipogenesis differentiation induction periods of 0, 7, 14, and 21 days, respectively. Values ​​determined by quantitative RT-PCR were ER7-A7 positive on day 0 ( ) Gene expression of hMSCs differentiated on the indicated day compared to hMSCs (2 -ΔΔCT It was displayed as the average multiple change of ). The graph values ​​used were the average values ​​after 2 repetitions. Figure 17 is a graph analysis of the relative ratio of positive to negative integrins αV and α3 positive and negative expression changes during osteocytic and adipogenesis differentiation of hMSCs. (A) After isolating hMSCs with MR1-B1 (integrin αV), positive and negative cells were differentiated into osteocytes and adipocytes for 14 and 21 days, respectively, and the expression ratios of osteocytic markers (RUNX2, OSX, COL1A1), osteocytic / adipocyte common markers (ALP), and adipogenesis markers (C / EBPA) in positive and negative groups were shown. When differentiating into osteocytes, it can be seen that RUNX2 (59-fold) and OSX (5118-fold) significantly increased in MR1-B1 positive cells on day 21. When differentiating into adipocytes, it can be seen that ALP (7838-fold) and CEBPA (4-fold) significantly increased in negative cells on day 21. Therefore, it can be seen that MR1-B1 positivity is a good marker for early osteocytosis, and positivity is a marker for adipogenesis. (B) After isolating hMSCs with ER7-A7 (integrin α3), positive and negative cells were differentiated into osteocytes and adipocytes for 14 and 21 days, respectively. Then, the expression ratios of osteocytosis markers (RUNX2, OSX, COL1A1), osteocytosis / adipocyte common marker (ALP), and adipogenesis marker (C / EBPA) were shown in the positive and negative groups. Upon differentiation into osteocytes, RUNX2 (5-fold), OSX (6-fold), and COL1A1 (3-fold) increased in ER7-A7 positive cells on day 21. Upon differentiation into adipocytes, ALP (14-fold) and CEBPA (5725-fold) increased in negative cells. Therefore, ER7-A7 positivity indicates a good marker for osteocytosis, and positivity indicates a good marker for adipogenesis. Figure 18 is a model of changes in the expression of integrins α2, α3, and αV during osteocytic differentiation of hMSCs. During osteocytic differentiation of hMSCs, integrin α2 expression is rapidly downregulated, while integrin α3 and αV expression are gradually upregulated. Integrin αV expression is also induced more rapidly in isolated integrin αV-negative (-) hMSCs, indicating that integrin αV induction is required for OB differentiation of hMSCs. Figure 19 shows the nucleotide and amino acid sequences of the variable region of the MR14-E5 antibody heavy chain gene, and is a figure showing the Complementarity Determining Region (CDR) that binds to the antigen and the residue positions of all amino acids. Figure 20 shows the nucleotide and amino acid sequences of the variable region of the MR14-E5 antibody light chain gene, and is a figure showing the Complementarity Determining Region (CDR) that binds to the antigen and the residue positions of all amino acids. Figure 21 shows the nucleotide and amino acid sequences of the variable region of the ER7-A7 antibody heavy chain gene, and is a figure showing the Complementarity Determining Region (CDR) that binds to the antigen and the residue positions of all amino acids. Figure 22 shows the nucleotide and amino acid sequences of the variable region of the ER7-A7 antibody light chain gene, and is a figure showing the Complementarity Determining Region (CDR) that binds to the antigen and the residue positions of all amino acids. Figure 23 shows the nucleotide and amino acid sequences of the variable region of the MR1-B1 antibody heavy chain gene, and is a figure showing the Complementarity Determining Region (CDR) that binds to the antigen and the residue positions of all amino acids. Figure 24 shows the nucleotide and amino acid sequences of the variable region of the MR1-B1 antibody light chain gene, and is a figure showing the Complementarity Determining Region (CDR) that binds to the antigen and the residue positions of all amino acids. Specific details for implementing the invention

[0049] The present invention will be described in detail below. Unless otherwise specifically defined, all terms in this specification have the same general meaning as understood by a person skilled in the art to which the present invention pertains. In the event of a conflict with the meaning of a term used in this specification, the meaning used in this specification shall prevail.

[0051] The present invention relates to a mesenchymal stem cell-specific monoclonal antibody comprising a heavy chain variable region and a light chain variable region.

[0052] The monoclonal antibody of the present invention comprises a CDR of a heavy chain variable region and a light chain variable region, and the CDR portion of the present invention has a nucleotide sequence that specifically binds to integrin α2-expressing mesenchymal stem cells or mesenchymal stem cells having osteocytic differentiation ability. In addition, the nucleotide sequence of the monoclonal antibody excluding the CDR portion is not limited.

[0053] The nucleotide sequence of the monoclonal antibody of the present invention may include not only the nucleotide sequences of Figures 19 to 24, but also nucleotide sequences having at least 80% homology thereto. Specifically, any nucleotide sequence capable of coating a protein composed of an amino acid sequence having at least 80% homology with the amino acid sequences of Figures 19 to 24 is included in the scope of the present invention, and nucleotide sequences having high homology with respect to the nucleotide sequences of Figures 19 to 24, such as 70% or more, specifically 80% or more, and more specifically 90% or more, should also be interpreted as being included in the scope of the present invention.

[0054] In addition, some amino acid sequences constituting the monoclonal antibody may be in a modified form. In proteins and polypeptides, amino acid exchanges that do not alter the overall activity of the molecule are known in the art. The most commonly occurring exchanges are between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Tyr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly. Monoclonal antibodies with sequences modified from the amino acid sequences of the monoclonal antibody provided in the present invention through such exchanges may be included within the scope of the present invention. Furthermore, modified monoclonal antibodies in which structural stability against heat, pH, etc., or antibody activity is increased due to mutations or modifications in the amino acid sequence may also be included within the scope of the present invention.

[0055] In one embodiment of the present invention, a monoclonal antibody that specifically binds to mesenchymal stem cells having osteocytic differentiation ability comprises a heavy chain variable region comprising CDR-H1 with the amino acid sequence of SEQ ID NO. 1, CDR-H2 with the amino acid sequence of SEQ ID NO. 2, and CDR-H3 with the amino acid sequence of SEQ ID NO. 3, and a light chain variable region comprising CDR-L1 with the amino acid sequence of SEQ ID NO. 4, CDR-L2 with the amino acid sequence of SEQ ID NO. 5, and CDR-L3 with the amino acid sequence of SEQ ID NO. 6 (hereinafter, the first antibody MR1-B1).

[0056] In one embodiment of the present invention, a monoclonal antibody that specifically binds to integrin α2-expressing mesenchymal stem cells comprises a heavy chain variable region comprising CDR-H1 with the amino acid sequence of SEQ ID NO. 7, CDR-H2 with the amino acid sequence of SEQ ID NO. 8, and CDR-H3 with the amino acid sequence of SEQ ID NO. 9, and a light chain variable region comprising CDR-L1 with the amino acid sequence of SEQ ID NO. 10, CDR-L2 with the amino acid sequence of SEQ ID NO. 11, and CDR-L3 with the amino acid sequence of SEQ ID NO. 12 (hereinafter, second antibody MR14-E5).

[0057] In one embodiment of the present invention, a monoclonal antibody that specifically binds to mesenchymal stem cells having osteocytic differentiation ability comprises a heavy chain variable region comprising CDR-H1 with the amino acid sequence of SEQ ID NO. 13, CDR-H2 with the amino acid sequence of SEQ ID NO. 14, and CDR-H3 with the amino acid sequence of SEQ ID NO. 15, and a light chain variable region comprising CDR-L1 with the amino acid sequence of SEQ ID NO. 16, CDR-L2 with the amino acid sequence of SEQ ID NO. 17, and CDR-L3 with the amino acid sequence of SEQ ID NO. 18 (hereinafter, third antibody ER7-A7).

[0058] In the present invention, the antibody may be an antibody in its whole form (hereinafter referred to as "whole antibody") or a functional fragment thereof. The whole antibody may be in the form of a monomer or a polymer in which two or more whole antibodies are combined. The functional fragment of the antibody is an antibody having a heavy chain and a light chain variable region of the whole antibody, and means recognizing an antigen-binding site (epitope) substantially identical to that recognized by the whole antibody. The functional fragment of the antibody includes, but is not limited to, a single-chain variable region fragment (scFv), (scFv)2, Fab, Fab', and F(ab')2, etc. The single-chain variable region (scFv) refers to an antibody fragment that takes the form of a single-chain polypeptide, in which a heavy chain variable region and a light chain variable region are connected via a linker peptide.

[0059] The above antibody may be modified by binding with various molecules such as enzymes, fluorescent substances, radioactive substances, and proteins. The modified antibody may be obtained by chemically modifying the antibody. Such modification methods are commonly used in the art. Additionally, the above antibody may be obtained as a chimeric antibody in which a variable region derived from a non-human antibody is combined with a constant region derived from a human antibody, or as a humanized antibody in which a framework region (FR) derived from a human antibody and a constant region are combined, including a complementarity determining region derived from a non-human antibody. Such antibodies may be prepared using methods known in the art.

[0060] In one embodiment of the present invention, the first antibody, which is a monoclonal antibody specific to mesenchymal stem cells having osteocytic differentiation ability, can be produced by hybridoma cells (MR1-B1 cells).

[0061] In one embodiment of the present invention, the second antibody, which is a mesenchymal stem cell-specific monoclonal antibody, can be produced by hybridoma cells (MR14-E5 cells).

[0062] In one embodiment of the present invention, the third antibody, which is a monoclonal antibody specific to mesenchymal stem cells having osteocytic differentiation ability, can be produced by hybridoma cells (ER7-A7 cells). In this specification, “hybridoma” refers to a hybrid cell obtained by fusing a tumor cell and a normal cell having a certain function. Since a cell is obtained that possesses both the proliferative properties of a tumor cell and the functions of a living cell, it is used for the production of monoclonal antibodies, etc.

[0063] In one embodiment of the present invention, to obtain a monoclonal antibody, mice required for the production of hybridoma cells that produce it must be immunized. To this end, bait cells A549 are injected into the sole of the right hind paw of a BALB / c mouse, and 3 days later, TGF-β1-treated A549 cells are injected into the sole of the left hind paw of the same mouse. After repeating the injections 7 times at 3-day intervals, lymphocyte fractions isolated from the left patellar lymph node are fused to FO myeloma with polyethylene glycol 1500. The fused cells are maintained in DMEM (Corning, Seoul, Korea) supplemented with 20% FBS (Welgene, Daegu, Korea), HAT supplement (Sigma-Aldrich), and antibiotic-antimicrobial solution (Welgene), and hybridoma clones specific to TGF-β-treated A549 cells are selected by flow cytometry analysis.

[0064] The hybridoma cell (MR1-B1 cell) according to the present invention and the monoclonal antibody (MR1-B1) produced therefrom show a high expression level of the osteocytic antigen integrin αV. Therefore, it can be seen that the hybridoma cell of the present invention and the monoclonal antibody produced therefrom have high binding specificity to the osteocytic antigen (integrin αV).

[0065] The hybridoma cell (ER7-A7 cell) according to the present invention and the monoclonal antibody (ER7-A7) produced therefrom show a high expression level of the osteocytic antigen integrin α3. Therefore, it can be seen that the hybridoma cell of the present invention and the monoclonal antibody produced therefrom have high binding specificity to the osteocytic antigen (integrin α3).

[0066] In addition, the hybridoma cell (MR14-E5) according to the present invention and the monoclonal antibody (MR14-E5) produced therefrom show a high expression level of the human mesenchymal stem cell antigen (integrin α2). Therefore, it can be seen that the hybridoma cell of the present invention and the monoclonal antibody produced therefrom have high binding specificity to the human mesenchymal stem cell antigen (integrin α2).

[0067] In this specification, “immunoglobulin” refers to a glycoprotein molecule produced as an immune response in response to antigenic stimulation. It primarily binds specifically to certain antigens within the blood to trigger an antigen-antibody reaction. Also known as an antibody, it is produced by B lymphocytes and performs the function of eliminating antigens of pathogenic microorganisms, such as bacteria and viruses, through precipitation or agglutination reactions. In addition, immunoglobulins induce various immune functions through interactions with other elements of the immune system.

[0068] Immunoglobulin is a glycoprotein structure composed of amino acids and sugar chains, consisting of a typical Y-shaped protein in which two light protein chains (light chains) and two heavy protein chains (heavy chains) are joined by disulfide bonds. Immunoglobulins contain multiple domains; the N-terminals of the heavy and light chains consist of variable regions with different amino acid compositions for each immunoglobulin, while the remaining parts consist of constant regions with a fixed amino acid composition specific to each type of immunoglobulin. The variable regions in the heavy and light chains of immunoglobulins combine to form a structure capable of binding to antigens, and the regions of each chain that bind to the antigen are called complementarity-determining regions (CDRs). The constant region in the heavy chain of immunoglobulin exists in several different forms, and depending on these forms, immunoglobulin can be classified into five isotypes, each of which includes IgG, IgA, IgD, IgM, IgE, etc.

[0069] In this specification, the term “monoclonal antibody (MAb)” refers to an antibody with identical characteristics produced by a single B cell that proliferates upon stimulation by an antigen and forms a clone. A monoclonal antibody is an antibody with a single affinity that binds to only one epitope. Recently, monoclonal antibodies are being produced using hybridoma generation techniques and are being utilized in practical applications such as many biological studies, disease diagnosis, and neutralization of toxins.

[0070] In this specification, “Integrin” refers to a substance that acts as a bridge connecting a cell to the extracellular matrix (ECM). It transmits chemical or mechanical changes from outside the cell into the cell, triggering intracellular signal transduction responses, which in turn alter the cell cycle, cell shape, and movement. Conversely, it also transmits changes from inside the cell to the outside. Integrin is a dimer composed of two strands, an α-chain and a β-chain, and is a type I membrane protein having a short C-terminal structure and a long N-terminal structure outside the cell. There are various types of α-chains and β-chains, and there are more than 24 integrins depending on the combination of these α-chains and β-chains.

[0071] In this specification, “mesenchymal stem cell (MSC)” refers to a cell that retains stemness and self-renewal ability and possesses plasticity, the ability to differentiate into various mesenchymal tissues. For example, mesenchymal stem cells can differentiate into bone (osteocytes), cartilage, muscle, bone marrow, tendons, adipose tissue, and connective tissue.

[0072] Mesenchymal stem cells include bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, umbilical cord blood-derived mesenchymal stem cells, placenta-derived mesenchymal stem cells, and umbilical cord-derived mesenchymal stem cells. However, they are not limited to these.

[0073] In this specification, “osteoblast (OB)” refers to a cell that has the ability to synthesize and secrete bone matrix and calcify bone tissue by depositing inorganic salts such as Ca and Mg ions into the matrix. “Osteocyte” refers to a cell that exists alone within a bone lacunae arranged at regular intervals, surrounded by substances secreted by osteoblasts and deposited with minerals.

[0074] In one embodiment of the present invention, a sample isolated from an individual may comprise mesenchymal stem cells expressing integrin α2. Additionally, the sample may comprise mesenchymal stem cells having osteocytic differentiation ability. Additionally, the sample may comprise mesenchymal stem cells having adipocyte differentiation ability. However, it is not limited thereto.

[0075] In the present invention, mesenchymal stem cells having osteocytic differentiation potential refer to mesenchymal stem cells that have a high osteogenetic potential and a high probability of differentiating into osteocytes. Additionally, mesenchymal stem cells having adipocyte differentiation potential refer to mesenchymal stem cells that have a high adipogenetic potential and a high probability of differentiating into adipocytes. However, they are not limited thereto and are pluripotent stem cells capable of differentiating into not only bone (osteocytes) or adipocytes, but also cartilage, muscle, bone marrow, tendons, or connective tissue.

[0077] The present invention relates to a composition for selecting integrin α2-expressing mesenchymal stem cells comprising a monoclonal antibody specific to integrin α2-expressing mesenchymal stem cells. Furthermore, the present invention relates to a composition for selecting stem cells having osteocytic differentiation ability comprising a monoclonal antibody specific to stem cells having osteocytic differentiation ability. Additionally, the present invention relates to a composition for selecting stem cells having osteocytic differentiation ability comprising a monoclonal antibody specific to stem cells having adipocyte differentiation ability. One embodiment of the present invention provides a composition for selecting mesenchymal stem cells having osteocytic differentiation ability, characterized by comprising a monoclonal antibody (at least one of a first or third antibody) that specifically binds to mesenchymal stem cells having osteocytic differentiation ability, and selecting cells that undergo an antigen-antibody binding reaction with the first or third antibody as mesenchymal stem cells having osteocytic differentiation ability.

[0078] One embodiment of the present invention provides a composition for selecting mesenchymal stem cells having adipocyte differentiation ability, comprising a monoclonal antibody (at least one of a first or third antibody) that specifically binds to mesenchymal stem cells having osteocytic differentiation ability, and selecting cells that do not undergo an antigen-antibody binding reaction with the first or third antibody as mesenchymal stem cells having adipocyte differentiation ability.

[0079] In one embodiment of the present invention, a composition for selecting mesenchymal stem cells is provided, characterized by including a monoclonal antibody (second antibody) that specifically binds to integrin α2-expressing mesenchymal stem cells, and selecting mesenchymal stem cells from a biological sample through an antigen-antibody binding reaction.

[0080] In the present invention, biological samples may include, but are not limited to, samples such as tissues, cells, whole blood, serum, plasma, saliva, sputum, and urine obtained from mammals. Before use for detection, the samples may be pretreated by filtration, distillation, extraction, concentration, inactivation of interfering components, addition of reagents, etc.

[0081] Since the composition of the present invention includes the monoclonal antibody described above, any redundant details are omitted to avoid excessive complexity in this specification.

[0083] The present invention relates to a kit for selecting integrin α2-expressing mesenchymal stem cells comprising a composition for selecting integrin α2-expressing mesenchymal stem cells. Furthermore, the present invention relates to a kit for selecting mesenchymal stem cells having osteocytic differentiation ability comprising a composition for selecting mesenchymal stem cells having osteocytic differentiation ability. Additionally, the present invention relates to a kit for selecting mesenchymal stem cells having adipocyte differentiation ability comprising a composition for selecting mesenchymal stem cells having adipocyte differentiation ability.

[0084] In one embodiment of the present invention, a kit for selecting mesenchymal stem cells having osteocytic differentiation ability is provided, comprising a selection composition including a first antibody or a third antibody, and characterized by selecting cells that undergo an antigen-antibody binding reaction with the first or third antibody as mesenchymal stem cells having osteocytic differentiation ability.

[0085] In one embodiment of the present invention, a kit for selecting mesenchymal stem cells having adipocyte differentiation ability is provided, comprising a selection composition including a first antibody or a third antibody, and characterized by selecting cells that do not undergo an antigen-antibody binding reaction with the first or third antibody as mesenchymal stem cells having adipocyte differentiation ability.

[0086] The present invention provides a kit for selecting integrin α2-expressing mesenchymal stem cells, comprising a selection composition containing a second antibody, and characterized by selecting cells that undergo an antigen-antibody binding reaction with the second antibody as integrin α2-expressing mesenchymal stem cells.

[0087] The kit for selecting mesenchymal stem cells having osteocytic differentiation ability according to the present invention can determine the degree of differentiation of mesenchymal stem cells and the degree of osteoblast expression by measuring the expression level of integrin αV or α3 in a biological sample through an antigen-antibody binding reaction using a monoclonal antibody that specifically binds to integrin αV or α3, which are markers of mesenchymal stem cells having osteocytic differentiation ability. In addition, it can be used to selectively isolate and culture mesenchymal stem cells having osteocytic differentiation ability from a sample, or to increase the purity of integrin α2-expressing mesenchymal stem cells in the remaining sample through the selective isolation of mesenchymal stem cells having osteocytic differentiation ability.

[0088] The kit for selecting mesenchymal stem cells capable of differentiating into adipocytes according to the present invention can determine the degree of differentiation of mesenchymal stem cells and the degree of adipocyte expression by measuring the expression level of integrin αV or α3 in a biological sample through an antigen-antibody binding reaction using a monoclonal antibody that specifically binds to integrin αV or α3, which are markers of mesenchymal stem cells capable of differentiating into osteocytes. In addition, it can be used to selectively isolate and culture mesenchymal stem cells capable of differentiating into adipocytes from a sample, or to increase the purity of integrin α2-expressing mesenchymal stem cells in the remaining sample through the selective isolation of mesenchymal stem cells capable of differentiating into adipocytes.

[0089] The kit for selecting integrin α2-expressing mesenchymal stem cells according to the present invention can determine the degree of differentiation of mesenchymal stem cells by measuring the expression level of integrin α2 in a biological sample through an antigen-antibody binding reaction using a monoclonal antibody that specifically binds to integrin α2, a mesenchymal stem cell marker. In addition, it can be used to selectively isolate and culture mesenchymal stem cells from a sample, or to increase the purity of mesenchymal stem cells with osteocytic differentiation ability or adipocyte differentiation ability in the remaining sample through the selective isolation of integrin α2-expressing mesenchymal stem cells.

[0091] The present invention relates to a method for selecting integrin α2-expressing mesenchymal stem cells comprising a composition for selecting integrin α2-expressing mesenchymal stem cells. Furthermore, the present invention relates to a method for selecting mesenchymal stem cells having osteocytic differentiation ability comprising a composition for selecting mesenchymal stem cells having osteocytic differentiation ability. Additionally, the present invention relates to a method for selecting mesenchymal stem cells having adipocyte differentiation ability comprising a composition for selecting mesenchymal stem cells having adipocyte differentiation ability.

[0092] In one embodiment of the present invention, a method for selecting mesenchymal stem cells having osteocytic differentiation ability includes the step of mixing and contacting a biological sample with a first antibody or a third antibody, and in the step, cells that undergo an antigen-antibody binding reaction with the first or third antibody can be selected as mesenchymal stem cells having osteocytic differentiation ability.

[0093] In one embodiment of the present invention, a method for selecting mesenchymal stem cells having adipocyte differentiation ability includes the step of mixing and contacting a biological sample with a first antibody or a third antibody, and in the step, cells that do not undergo an antigen-antibody binding reaction with the first or third antibody can be selected as mesenchymal stem cells having adipocyte differentiation ability.

[0094] In one embodiment of the present invention, a method for selecting integrin α2-expressing mesenchymal stem cells comprises the step of mixing and contacting a biological sample with one or more antibodies from a group consisting of a second antibody, and in the step, cells that undergo an antigen-antibody binding reaction with the second antibody can be selected as integrin α2-expressing mesenchymal stem cells.

[0095] This can be performed by mixing a biological sample with the screening composition of the present invention. Alternatively, it can be performed by applying the biological sample to the screening kit of the present invention. However, it is not limited thereto.

[0096] Hereinafter, the present invention will be described in detail with reference to examples to specifically explain the invention. However, the following examples are provided merely to facilitate a better understanding of the invention, and the scope of the invention is not limited by these examples.

[0098] Examples

[0099] 1. Preparation of a monoclonal antibody group that specifically binds to TGFβ1-treated A549 lung cancer cells.

[0100] 1-1. Characterization of A549 lung cancer cells with EMT induced by TGFβ1 treatment.

[0101] Human non-small cell lung cancer (NSCLC) A549 cells were purchased from the Korea Cell Line Bank (KCLB, Seoul) and cultured according to the protocol provided by the supplier. Human peripheral blood mononuclear cells (PBMCs) were isolated using the Ficoll-Paque Plus method (GE Healthcare, Seoul, Korea). To induce EMT in A549 cells, cells were prepared at a rate of 1.8 x 10⁶ 4 Cells / cm 2 It was inoculated and cultured for 24 hours.

[0102] In this specification, “Peripheral blood mononuclear cell (PBMC)” refers to any peripheral blood cell having a round nucleus. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes, whereas red blood cells and platelets lack a nucleus, and granulocytes (neutrophils, basophils, and eosinophils) have a multilobed nucleus. Human lymphocytes constitute the majority of the PBMC population, as well as monocytes and dendritic cells.

[0103] In this specification, “Epithelial to Mesenchymal Transition (EMT)” refers to the theory that epithelial stem cells or differentiated epithelial cells transform into tumor cells with mesenchymal characteristics as they accumulate somatic mutations. It explains cancer metastasis based on the fact that individual cancer cells acquire mesenchymal characteristics and move away from the primary tumor to the blood vessels.

[0104] Next, cells were treated with 5 ng / ml TGF-β1 (Peprotech, Rockyhill, NJ, USA), and the medium was changed every 2 days. As a result, TGF-β1-treated A549 cells became elongated into fibroblast-like cell shapes (see Fig. 1A). To analyze EMT-related molecules by Western blotting, one million A549 cells were treated with TGF-β1 for 4 days, then cells were detached with Trypsin-EDTA, total proteins were separated using 10% SDS-PAGE, transferred to a nitrocellulose membrane for Western blotting, and the membrane was blocked with 5% (w / v) skim milk powder at room temperature for 1 hour. After washing three times with 0.1% (v / v) PBST (phosphate buffered saline, 0.1% tween-20), ZEB1 (Santa Cruz Biotechnology, Santa Cruz, CA), vimentin (Santa Cruz Biotechnology), Slug (Santa Cruz Biotechnology), hnRNPA2 / B1 (Abcam), -actin (Santa Cruz Biotechnology) The corresponding antibodies were conjugated at room temperature for 1 hour, washed 3 times with 0.1% (v / v) PBST, and incubated with HRP-conjugated anti-mouse (Merck Millipore) or rabbit IgG (Abcam) for another 1 hour at room temperature. Then West-Queen TMConfirmation was performed using a Western blot detection system (iNtRONBiotechnology). The results showed increased expression of mesenchymal markers, including ZEB1, vimentin, Slug, and hnRNPA2 / B1, while the epithelial marker E-cadherin was decreased (see Fig. 1B). Additionally, for the analysis of cell surface molecules by flow cytometry (FACS), A549 cells were isolated as single cells using TrypLE (Invitrogen), passed through a 40 μm strainer, and approximately 2–3 x 10⁶ cells were obtained per sample. 5 Cells were used. After incubating with antibodies for E-cadherin (Santa Cruz Biotechnology), EpCAM (Abcam), and N-cadherin (Santa Cruz Biotechnology) at 4°C for 30 minutes and washing twice with PBA (1% bovine serum albumin, 0.02% NaN3in PBS), the cells were further incubated with the primary antibody's corresponding anti-mouse IgG-FITC (BD Biosciences) or anti-rabbit IgG-FITC (Abcam) at 4°C for 30 minutes. After washing twice with PBA, antibody binding on PI (propidium iodide)-negative cells was analyzed using FACSCalibur and Cell Quest software (BD sciences). The results showed that cell surface expression of epithelial markers E-cadherin and EpCAM was downregulated in TGF-β1-treated A549 cells, while cell surface expression of the mesenchymal marker N-cadherin was slightly upregulated (see Fig. 1C). The results indicate that TGF-β1 induces A549 epithelial cells to undergo the EMT process, consistent with previous studies.

[0106] 1-2. Decoy immunization for the preparation of antibodies specific to TGF-β1-treated A549.

[0107] To generate hybridomas that produce antibodies specific to TGF-β1-treated A549 cells, one million A549 bait cells were injected into the right hind paw of female BALB / c mice (DBL, Chungbuk, Korea), and three days later, one million TGF-β1-treated A549 cells were injected into the left hind paw of the same mice. After repeating the injections seven times at three-day intervals, lymphocyte fractions isolated from the left patellar lymph node were fused with FO myeloma cells (ATCC) using polyethylene glycol 1500 (Roche, Seoul, Korea). The fused cells were maintained in DMEM (Corning, Seoul, Korea) supplemented with 20% FBS (Welgene, Daegu, Korea), HAT supplement (Sigma-Aldrich), and antibiotic-antimicrobial solution (Welgene). Hybridoma clones specific to TGF-β1-treated A549 cells were selected by flow cytometry. The antibodies produced from the three final selected antibodies from a total of 263 hybridomas—MR14-E5, ER7-A7, and MR1-B1—showed increased binding affinity to TGF-β1-treated A549 cells compared to A549 cells (see Fig. 2). The isotypes of antibodies secreted from the hybridoma cells MR14-E5, ER7-A7, and MR1-B1 were analyzed using a mouse immunoglobulin isotyping kit (BD Biosciences, Seoul, Korea) (see Table 1), and the antibodies were also purified using protein G agarose column chromatography (Merck Millipore).

[0108] Analysis results of isotypes of antibodies secreted from hybridoma using a mouse immunoglobulin isotyping kit. antibodies Flow cytometric analysis clone Isotype A549 TGFβ PBMC E-Cadherin ND ++ + (↓) ND N-cadherin ND + + (↑) ND MR14-E5 IgG2a, κ + ++ (↑) - ER7-A7 IgG1, κ +++ +++ (↑) - MR1-B1 IgG2a, κ ++ ++ (↑) -

[0109] 1-3. Binding analysis of selected antibodies to human bone marrow-derived mesenchymal stem cells and bone progenitor cells.

[0110] Human fetal osteoblast cell line hFOB1.19 was purchased from ATCC (CCRL-11372, Manassas, VA) and cultured according to the protocol provided by the supplier. Human bone marrow-derived mesenchymal stem cells (hMSCs) were kindly provided by Professor Sung-Su Kim (Ajou University School of Medicine, Suwon, Korea). hMSCs were cultured in DMEM (Welgene, Daegu, Korea) basal medium supplemented with 20 ng / ml bFGF (R&D system, Minneapolis, MN), 10% fetal bovine serum (FBS) (Biowest, Nuaille, Pays de la loire, France), 100 U / ml penicillin G (Welgene), and 100 µg / ml streptomycin (Welgene) using cm 2 5.0X10 per 3 It was inoculated and cultured. The medium was changed every two days, and subculture was performed every week. Cells from passages 4-6 were used in the experiment.

[0111] In this specification, “subculture” refers to the cultivation of new cells or microorganisms created by transferring some cells from an original culture to a new culture medium. Subculture is used to increase the number of cells of plants and animals or microorganisms, or to extend the lifespan of cell lines to maintain them for a long time.

[0112] To observe whether the target antigens of selected mAbs are expressed in human bone marrow-derived mesenchymal stem cells (hMSCs) and osteogenic progenitor cells (hFOBs) with osteogenic ability, the cell surface expression of the target antigens of selected mAbs was investigated by flow cytometry with mAbs in two human osteogenic progenitor cells (hMSCs and hFOBs) and two human osteoblast carcinoma cell lines (U2OS and SAOS-2).

[0113] In this specification, “flow cytometry” refers to a technique for measuring the number of cells, organisms, and other biological particles dispersed in a liquid, as well as their respective physical, chemical, and biological characteristics. A liquid is flowed through a measurement site and measured using electrical, optical, or acoustic methods.

[0114] The red-filled histogram represents the allotype control. For FACS analysis, cells were isolated as single cells using TrypLE (Invitrogen), passed through a 40 μm strainer, and then approximately 2–3 x 10⁶ cells were strained per sample. 5Cells were used. After incubating with CD146, MR14-E5, ER7-A7, and MR1-B1 antibodies at 4°C for 30 minutes, the cells were washed twice with PBA (1% bovine serum albumin, 0.02% NaN3in PBS), and then incubated with anti-mouse IgG-FITC (BD Biosciences), which corresponds to the primary antibodies, for an additional 30 minutes at 4°C. After washing twice with PBA, antibody binding to PI (propidium iodide)-negative cells was analyzed using FACSCalibur and Cell Quest software (BD sciences). As a result, the bone progenitor marker CD146 bound to osteogenic progenitor cells (hMSC, hFOB) and human osteoblast cancer cell lines (U2OS and SAOS-2), while the MR14-E5 antibody failed to bind to SAOS-2 but bound to the remaining hMSCs, hFOB, and U2OS; meanwhile, ER7-A7 and MR1-B1 both bound well to human osteogenic progenitor cells (hMSC, hFOB) and human osteoblast cancer cell lines (U2OS and SAOS-2), indicating that they are antibodies that recognize molecules expressed on bone progenitor cells (see Fig. 3). Additionally, human peripheral blood mononuclear cells (PBMCs) were isolated using the Ficoll-Paque Plus method (GE Healthcare, Seoul, Korea), and the antibodies hardly bound to the PBMCs, indicating that they recognize surface antigens specifically expressed on bone progenitor cells (see Fig. 3).

[0116] 2. Binding analysis of antibodies selected during osteoblast (OB) differentiation.

[0117] Next, the inventors investigated the cell surface expression of target antigens of selected MR14-E5, ER7-A7, and MR1-B1 antibodies during the osteogenic differentiation of hMSCs. To promote the differentiation of hMSCs into OBs, hMSCs were treated with 1 ng / ml TGF-β1 and 10 ng / ml BMP-2 for 14 days. As a result, CD146, a marker of osteoblasts (Sacchetti, Funari et al. 2007), increased, and the target antigens of MR14-E5, ER7-A7, and MR1-B1 antibodies also increased (see Fig. 4). In addition, to induce the differentiation of hMSCs into osteocytes, cm 2 1.0X10 per 4hMSCs inoculated with [the substance] were cultured in osteogenic differentiation medium (ODM) supplemented with 10% FBS (Biowest), 100 U / mL penicillin G (Welgene), 100 µg / mL streptomycin (Welgene), 100 nM dexamethasone (Sigma-Aldrich, St. Luis, MO), 60 uM L-ascorbic acid (Sigma-Aldrich), and 10 mM β-glycerol phosphate (Sigma-Aldrich) in DMEM (Welgene) free of phenol red. Differentiation was carried out for 12 days, with the medium being replaced with fresh medium every 3 days for the first week after inoculation, and then every 2 days thereafter. The presence of OB differentiation and the cell surface expression of target antigens of MR14-E5, ER7-A7, and MR1-B1 antibodies in the differentiated OBs were analyzed by flow cytometry. Whether OBs were formed by differentiating hMSCs into ODMs was measured using Alizarin Red S (ARS) staining. For ARS staining, cells were incubated overnight in 4% paraformal dehydrogenase and then incubated with 2% Alizarin Red S staining solution at room temperature for 10 minutes. After washing five times with distilled water, calcium-deposited bone nodules were observed under a microscope. As a result, bone nodules were observed, indicating that differentiation into osteoblasts had progressed well (see Fig. 4A). Under these conditions, target antigens of antibodies including CD146, ER7-A7, and MR1-B1 increased, indicating that these antigens are proportional to OB differentiation, while the MR14-E5 target antigen decreased, indicating an inverse relationship (see Fig. 4D). Runx2 is a major transcription factor positively associated with the OB phenotype that maintains the immature state of OB, thereby preventing OB from maturing into final osteocytes and inhibiting the differentiation of hMSCs into adipocytes or chondrocytes.Therefore, to observe whether the MR14-E5, ER7-A7, and MR1-B1 antigens on the surface of OB are affected by Runx2 expression, the Runx2 gene was knockdowned in U2OS cells. First, using siRNA oligonucleotides targeting RUNX2 (Santa Cruz Biotechnology) or a control siRNA (Bioneer, Daejeon, Korea), U2OS cells (2.6 x 10⁶) were induced using the Lipofetamine RNAiMAX reagent (Thermo Fischer Scientific). 4 Cells / cm 2Cells were transfected with 50 nM control or RUNX2 siRNA. After 24 hours, cells were transfected once more (double knockdown) and harvested for analysis after 48 hours. Cells were collected by trypsin-EDTA (Welgene), and total RNA was extracted by RNAiso Plus (TaKaRa) according to the manufacturer's instructions. To perform RT-PCR, cDNA was synthesized with Prime Script™ RT Master Mix (TaKaRa), and PCR was performed using e-Taq DNA Polymerase (SolGent, Daejeon, Korea). Each gene was analyzed three times, consisting of denaturation at 95 °C for 1 minute, annealing at 56–67 °C for 45 seconds, and extension for 30 cycles at 72 °C for 45 seconds. The primer sequences for Runx2 and GAPDH used are listed in Table 2. As a result, a decrease in Runx2 expression was observed in knockdown cells (see Fig. 4B). Additionally, the same results were obtained when Runx2 protein expression was analyzed by Western spectroscopy (see Fig. 4C). Under these conditions, there was no significant change in CD146, but the cell surface expression of the target antigens ER7-A7 and MR1-B1 was downregulated in Runx2 knockdown U2OS cells, whereas the expression of the MR14-E5 surface antigen was upregulated (see Fig. 4D). Taken together, the results showed that ER7-A7 and MR1-B1 antigens were upregulated during osteogenic differentiation of hMSCs, while MR14-E5 antigens were downregulated; thus, it was found that the target antigens ER7-A7 and MR1-B1 act as positive markers for OB, and the target antigen MR14-E5 acts as a negative marker for OB and a positive marker for hMSCs.

[0119] 3. Identification of antigens recognized by MR14-E5, ER7-A7, and MR1-B1.

[0120] 3-1. Identification of cell surface protein molecules recognized by MR14-E5, ER7-A7, and MR1-B1.

[0121] Biotinylation of the A549 cell surface, which exhibits binding affinity to MR14-E5, ER7-A7, and MR1-B1 antibodies, was performed by slightly modifying the protocol provided by EZ-Link Sulfo-NHS-LC-Biotin (Pierce). A549 cells cultured in 100-millimeter cell culture plates were washed twice with PBS (pH 7.4) at 37°C, then cold PBS (pH 8.0) containing dissolved Biotin (0.5 mg / ml) was added, and the mixture was incubated at 4°C for 30 minutes. After washing three times with cold PBS (pH 8.0), biotin-labeled cells were incubated in lysis buffer (25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 2 µg / ml aprotinin, 100 µg / ml PMSF, and 5 µg / ml leupeptin, 1 mM NaF, 1 mM Na3VO4) at 4°C for 30 minutes, followed by nucleation by centrifugation at 12,000 rpm for 40 minutes before use. To remove proteins that bind nonspecifically to Protein-G agarose (Santa Cruz Biotechnology), approximately 1 x 10 720 µl of Protein-G agarose was added to the cell lysate and incubated at 4°C for 2 hours. The Protein-G agarose was then recovered by centrifugation, and the sample washed 4–5 times with lysis buffer was used as a negative control. To immunoprecipitate antigens recognized by monoclonal antibodies MR14-E5, ER7-A7, and MR1-B1, 2 µg of each antibody was added to the cell lysate from which proteins non-specifically binding to Protein-G agarose had been removed, and the mixture was incubated at 4°C for 12 hours. Subsequently, 20 µl of Protein-G agarose was added and incubated for an additional 2 hours at 4°C. The immunoprecipitated immunomixture was washed 4–5 times with lysis buffer, 5x sample buffer was added to elute the antigens bound to each antibody, and the mixture was boiled at 100°C for 5 minutes. The negative control protein and the eluted protein were separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then Western blotting was performed on a nitrocellulose membrane. The membrane was blocked with 5% skim milk powder at room temperature for 1 hour. After washing three times with 0.1% PBST, the mixture was incubated with streptavidin-HRP (1:7,000; GE healthcare) for an additional 1 hour at room temperature. After washing three times with 0.1% PBST, the biotin-labeled protein was identified using an ECL detection kit (GE healthcare). As a result, it was confirmed that the monoclonal antibody MR14-E5 immunoprecipitated a protein of approximately 150 kDa. It was confirmed that ER7-A7 and MR1-B1 immunoprecipitated a protein of approximately 130 kDa (see Fig. 5).

[0123] 3-2. Identification of antigens immunoprecipitated by monoclonal antibodies MR14-E5, ER7-A7, and MR1-B1.

[0124] SDS gels containing proteins immunoprecipitated by monoclonal antibodies MR14-E5, ER7-A7, and MR1-B1 were stained using a Commassie G250 (BIO-RAD) according to the supplier's protocol. The identified proteins were excised and sent to Proteomtech (Seoul, Korea) for analysis using LC-MS / MS mass spectrometry. As a result, it was confirmed that the target antigen of MR14-E5 was integrin α2, ER7-A7 was integrin α3, and MR1-B1 was integrin αV (see Figures 6, 7, and 8).

[0126] 3-3. Verification of MR14-E5, ER7-A7, and MR1-B1 antigens by tagged integrin expression.

[0127] Rabbit polyclonal antibodies anti-integrin α2 (Mybiosource, San Diego, CA, USA), anti-integrin α3 (Sino Biological Inc, Wayne, PA, USA), and anti-integrin αV (Sino Biological Inc, Wayne, PA, USA) were purchased, and overexpression experiments were performed using tagged integrin expression vectors to reconfirm whether the proteins immunoprecipitated by monoclonal antibodies MR14-E5, ER7-A7, and MR1-B1 were integrin α2 (ITGA2), integrin α3 (ITGA3), and integrin αV (ITGAV), respectively. First, His-tagged ITGA2 expression plasmid (Sino Biological) and a gene-free control vector were transfected into HEK293T cells using Lipofectamine™ 2000 (Thermo Fischer Scientific) according to the supplier's protocol. Cell lysates were immunoprecipitated with MR14-E5, anti-His antibody, and anti-integrin α2 antibody, and the immunoprecipitates were detected with anti-integrin α2 or anti-His antibody. All immunoprecipitates were detected with anti-integrin α2 or anti-His antibody (see Fig. 9A), proving that the MR14-E5 antigen is indeed integrin α2. To demonstrate that ER7-A7 recognizes integrin α3, FLAG-tagged ITGA3 expression plasmid (Sino Biological) and a gene-free control vector were transfected into HEK293T cells, and cell lysates were immunoprecipitated with ER7-A7 and anti-integrin. α3 and anti-FLAG antibodies, and immunoprecipitates were detected with anti-integrin α3 or anti-FLAG antibody.All immunoprecipitates were detected with anti-integrin α3 or anti-FLAG antibodies (see Fig. 9B), indicating that the ER7-A7 antigen is integrin α3. To demonstrate that MR1-B1 recognizes integrin αV, a FLAG-tagged ITGAV-expressing plasmid (Sino Biological) and a gene-free control vector were transfected into HEK293T cells, cell lysates were immunoprecipitated with MR1-B1, anti-integrin αV, and anti-FLAG antibodies, and the immunoprecipitates were detected with anti-integrin αV or anti-FLAG antibodies. All immunoprecipitates were detected with anti-integrin αV or anti-FLAG antibodies (see Fig. 9C), indicating that the MR1-B1 antigen is indeed integrin αV.

[0129] 4. Analysis of expression of integrin α2, α3, and αV during osteoblast / adipocyte differentiation of hMSCs.

[0130] 4-1 Analysis of integrin α2, α3, and αV expression during osteoblast differentiation of hMSCs.

[0131] Next, the expression patterns of integrin α2, α3, and αV during OB differentiation of hMSCs were investigated. As in Example 2 above, the cells were cultured in osteogenic differentiation medium (ODM) for 0, 7, 14, and 21 days. In addition, to inhibit TGF-βs that suppress osteoblast terminal differentiation in the serum of the ODM culture medium, 1 μM of SB431542 (MedChemExpress, Monmouth Junction, NJ), a specific inhibitor of TGF-β1 receptor kinase, was added to the ODM starting from the 7th day of culture to promote osteoblast differentiation. Differentiation was carried out for 0, 7, 14, or 21 days, respectively, by changing to fresh medium every 3 days until one week after inoculation, and every 2 days thereafter. As in Example 2 above, the degree of osteogenic differentiation of hMSCs was observed by calcium deposition using a 2% ARS solution. Quantitative real-time PCR (qPCR) was performed to observe the expression of osteoblast-related differentiation genes during OB differentiation. First, to extract total RNA, total RNA was extracted from hMSCs and differentiated hMSCs using RNAiso Plus (TaKaRa) according to the manufacturer's protocol. cDNA was generated from total RNA by reverse transcriptase (RT) in a reaction containing 500 ng of total RNA and Prime Script RT Master Mix (TaKaRa). The RT reaction was performed at 37°C for 15 minutes, followed by heating at 94°C for 5 seconds. qPCR was performed using an Applied StepOne™ Real-Time PCR system equipped with SYBR Green reagent (Thermo Fischer Scientific). The standard reaction was carried out in a total volume of 25 μl using 12.5 μl of 2xPCR buffer (PowerUP™ SYBR™ Green Master Mix, Thermo Fischer Scientific), 2 μl of cDNA template, and 10 pM forward and reverse primers.PCR was performed for 30 cycles consisting of 1 minute at 95°C, 45 seconds at 45 to 56°C, and 1 minute at 72°C. Each sample was analyzed 3 times for each target gene.

[0132] Primer sequences for gene expression analysis of human mesenchymal stem cells. gene Forward Primer Reverse primer ITGA2 5'-CCTTGAAGCCTATTCTGAGACTGCC-3' (Sequence No. 37) 5'-AATTCCAGTGTTGTATGCACTTTCCC-3'(Sequence No. 38) ITGA3 5'-ACTGTGAAGGCACGAGTGTGGAAC-3'(Sequence No. 39) 5'-ATGCTGGTTCGGAGGAATAGGG-3'(Sequence No. 40) ITGAV 5'-GGATTGTTGCTACTGGCTGTTTTGG-3'(Sequence No. 41) 5'-TCCCTTTCTTGTTCTTCTTGAGGTGG-3'(Sequence No. 42) RUNX2 5'-GACCAGTCTTACCCCTCCTACC-3'(Sequence No. 43) 5'-CTGCCTGGCTCTTCTTACTGAG-3'(Sequence No. 44) ALP 5'-ACTCCCACTTCATCTGGAACC-3'(Sequence No. 45) 5'-CCTGTTCAGCTCGTACTGCAT-3'(Sequence No. 46) Col1A1 5'-GAGAGGAAGGAAAGCGAGGAG-3'(Sequence No. 47) 5'-GGGACCAGCAACACCATCT-3'(Sequence No. 48) OSX 5'-GCCAGAAGCTGTGAAACCTC-3'(Sequence No. 49) 5'-GCTGCAAGCTCTCCATAACC-3'(Sequence No. 50) CEBPA 5'-GGTGGACAAGAACAGCAACG-3'(Sequence No. 51) 5'-CGGTCATTGTCACTGGTCAG-3'(Sequence No. 52) GAPDH 5'-ACAGCGACACCCACTCCTCC-3'(Sequence No. 53) 5'-GAGGTCCACCACCCTGTTGC-3'(Sequence No. 54)

[0134] When comparing the culture without SB431542 and after the addition of SB431542, high calcium deposition was observed in the culture with the addition, indicating that hMSCs differentiated well into OBs (see Fig. 10A). To observe differentiation into osteoblasts and adipocytes, the expression of early osteoblast formation markers (RUNX2, OSX), late osteoblast markers (COL1A1), osteoblast and adipocyte common markers (ALP), and adipogenesis markers (C / EBPA) was analyzed at each differentiation stage. In cultures on day 21 supplemented with SB431542, high expression increases were observed by qPCR for the OB differentiation markers Runx2 (1008-fold), alkaline phosphatase (ALP, 360-fold), collagen type I (COL1A1, 15-fold), and osterix (OCX, 893-fold), while the adipocyte marker C / EBPA (1.8-fold) increased only slightly (see Fig. 10B). The apparent increase in early OB markers (Runx2, ALP, OSX) suggests that the differentiated hMSCs are primarily in the early OB stage. Under these circumstances, the expression level of integrin α2 mRNA (ITGA2) gradually decreased by 4.6-fold during osteoblastic differentiation of hMSCs (see Fig. 10B). The expression level of integrin α3 mRNA (ITGA3) was initially decreased until 14 days of osteoblastic differentiation in hMSCs, but was upregulated by approximately 0.7-fold at 21 days of osteoblastic differentiation in the presence of SB431542 (see Fig. 10B). The expression level of integrin αV mRNA (ITGAV) was slightly increased to about 1.5-fold at 14 days of osteoblastic differentiation in hMSCs, and then increased by approximately 5.3-fold at 21 days of osteoblastic differentiation in the presence of SB431542 (see Fig. 10B). These results suggest that during the maturation process of OB in hMSCs, integrin α2 is rapidly downregulated and integrin α3 initially decreases slightly before increasing again, while in the case of integrin αV, a more rapidly increased expression is required.

[0135] Next, the inventors investigated the cell surface expression of integrins α2, α3, and αV by flow cytometry during osteoblastic differentiation of hMSCs. The expression of CD73, CD90, CD146, and CD164 is also known as an hMSC or osteoprogenitor cell marker. CD90 and CD146 were significantly downregulated during osteoblastic differentiation of hMSCs, whereas CD73 and CD164 were upregulated during osteoblastic differentiation of hMSCs. Under these circumstances, the cell surface expression of integrin α2 (recognized by MR14-E5) was significantly downregulated during osteoblastic differentiation of hMSCs. The cell surface expression of integrin α3 (recognized by ER7-A7) was partially upregulated (106%) during osteoblastic differentiation on day 14, and then increased to approximately 176% during osteoblastic differentiation on day 21. Cell surface expression of integrin αV (recognized by MR1-B1) was upregulated by approximately 187% at day 21 of osteoblast differentiation, indicating that integrin α3 and αV expression increased during osteoblast differentiation (see Fig. 10C).

[0137] 4-2. Analysis of expression of integrin α2, α3, and αV during adipocyte differentiation of hMSCs.

[0138] The expression of the aforementioned integrins was also observed when hMSCs were differentiated into adipocytes for 0, 14, and 21 days. To induce the differentiation of hMSCs into adipocytes, cm 2 1.0X10 per 4 as Inoculated hMSCs were cultured in α-MEM (Welgene) in an adipocyte differentiation medium (ADM) supplemented with 10% FBS (Biowest), 100 U / ml penicillin G (Welgene), 100 μg / ml streptomycin (Welgene), 1 μM dexamethasone (Sigma-Aldrich), 60 μM indomethacin (Sigma-Aldrich), 500 μM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), and 10 μg / ml insulin (Sigma-Aldrich). The degree of differentiation into adipocytes was measured by staining the formed oil droplets. Wells that had differentiated into adipocytes were washed three times with PBS, treated with 1 ml of 10% paraformaldehyde at room temperature for 5 minutes, and after removing the paraformaldehyde, the wells were washed with 60% isopropanol. After drying for about 10 minutes, the wells were stained with 1 ml of 0.3% Oil Red O solution at room temperature for 10 minutes, and the wells were washed three times with 2 ml of distilled water before observation. As a result, oil droplets formed starting 14 days after differentiation into adipocytes were observed, confirming that adipocyte differentiation had progressed well. Under these conditions, osteoblast markers CD73, CD90, CD146, and CD164 were all rapidly decreased, and integrin α2 and integrin α3, including integrin αV, were all rapidly downregulated. These results indicate that during the differentiation of hMSCs into adipocytes, integrin α2 recognized by MR14-E5, integrin α3 recognized by ER7-A7, and integrin αV recognized by MR1-B1 are all rapidly downregulated (see Fig. 11). These results suggest that integrin α2 is an hMSC marker that decreases during both osteoblast and adipocyte differentiation of hMSCs, while integrin α3 and integrin αV are osteoblast markers that increase during osteoblast differentiation.

[0141] 5. Comparative analysis of integrin αV expression after hMSC sorting using MR1-B1 antibody.

[0142] 5-1. MR1-B1 Positive and negative Comparison of markers during osteoblast differentiation in hMSCs.

[0143] Next, the osteoblastic potential of MR1-B1 positive (+) and negative (-) hMSCs was investigated following MR1-B1-based autologous cell sorting. Antibodies were biotinized using the DSB-X Biotin Labeling Kit (Thermo Fischer Scientific) according to the manufacturer's protocol. To separate hMSCs into MR1-B1 positive (+) and negative (-) groups, 5 million hMSC cells were reacted with 20 µg of biotinized MR1-B1 antibody at room temperature for 30 minutes while shaking. Cell sorting was performed using the Dynabeads FlowComp Flexi Kit (Thermo Fischer Scientific) according to the manufacturer's protocol. Unconjugated hMSCs were isolated and analyzed with Alexa488-conjugated mouse IgG (Thermo Fischer Scientific) and FACSCalibur. Both sorted MR1-B1 positive (+) and negative (-) hMSCs were cultured in ODM for 21 days. As in Example 4-1, SB431542 was added to the ODM after 7 days of osteoblastic differentiation. All OB surface markers (CD73, CD90, CD146, and CD164) were slightly upregulated in MR1-B1 positive (+) hMSCs compared to MR1-B1 negative (-) hMSCs (Fig. 12A). Alizarin Red S staining indicated that MR1-B1 positive (+) hMSCs had greater osteoblastic potential than MR1-B1 negative (-) hMSCs (see Fig. 12B). During the 21-day osteoblastic differentiation process, at day 14, the expression levels of Runx2 and OSX in MR1-B1 positive (+) hMSCs were approximately 52-fold and 7.6 x 10⁶, respectively, compared to MR1-B1 negative (-) hMSCs. 4They were upregulated twofold, which are approximately 9-fold and 809-fold higher than in MR1-B1 negative (-) hMSCs (see Figs. 12C, 12D and Table 3). During 21 days of differentiation, the expression levels of Runx2 and OSX in MR1-B1 positive (+) hMSCs were approximately 2.7 x 10⁻¹⁰, respectively, compared to MR1-B1 negative (-) hMSCs. 4 and 8.7 x 10 6 It was significantly upregulated, which were approximately 59-fold and 5118-fold higher than in MR1-B1-negative (-) hMSCs (see Figs. 12C, 12D and Table 3). The expression level of COL1A1, a late OB marker, was progressively upregulated during 21 days of osteoblastic differentiation and was higher in MR1-B1-positive (+) hMSCs than in MR1-B1-negative (-) hMSCs, whereas the expression level of ALP was downregulated about 3-fold in MR1-B1-positive (+) hMSCs compared to MR1-B1-negative (-) hMSCs (see Figs. 12E, 12F and Table 3). The expression level of C / EBPA, an adipogenesis marker, was progressively upregulated in MR1-B1-negative (-) hMSCs and MR1-B1-positive (+) hMSCs during 21 days of osteoblastic differentiation, but was significantly lower, by about twofold, in MR1-B1-positive (+) hMSCs at the 21st day of differentiation (see Fig. 12G). Therefore, it can be seen that while the expression levels of major osteogenic transcription factors (Runx2, OSX) and COL1A1 were upregulated in MR1-B1-positive (+) hMSCs, the expression level of the adipogenesis transcription factor C / EBPA was downregulated in MR1-B1-positive (+) hMSCs during osteogenic differentiation of hMSCs. The results indicate that MR1-B1-positive (+) hMSCs have greater osteoblastic potential than MR1-B1-negative (-) hMSCs.

[0144] hMSC Osteogenic marker Common marker ALP Adipogenicmarker C / EBPA RUNX2 OSX COL1A1 14d 21d 14d 21d 14d 21d 14d 21d 14d 21d MR1-B1 ratio (+ / -) ODM 9X↑ 59X↑ 809X↑ 5118X↑ - - - 3X↓ 2X↓ 2X↓ ADM - - - - - - 4X↓ 7838X↓ 5X↓ 4X↓ ER7-A7 ratio (+ / -) ODM 4X↑ 5X↑ 7X↑ 6X↑ 2X↑ 3X↑ - - - 7X↓ ADM - 17X↓ 4X↓ - - 2X↓ 6X↓ 14X↓ 247X↓ 5725X↓

[0146] Table 3 presents the analysis of the relative ratio of positive to negative changes in the expression of integrins αV (MR1-B1) and α3 (ER7-A7) positive and negative during osteoblastic and adipogenesis differentiation of hMSCs. The expression of early osteoblastic markers (RUNX2, OSX), late osteoblastic markers (COL1A1), early-mid osteoblastic / adipogenesis common markers (ALP), and late adipogenesis markers (C / EBPA) was separated using respective antibodies, and the difference in expression ratios between positive and negative groups was shown. A difference in the positive / negative ratio of less than 1.5 times was indicated as ─.

[0148] 5-2. Comparison of markers during adipocyte differentiation in MR1-B1 positive and negative hMSCs.

[0149] When MR1-B1 positive (+) and negative (-) hMSCs isolated from hMSCs using the MR1-B1 antibody were differentiated into adipocytes for 0, 14, and 21 days, the expression of early osteoblast formation markers (RUNX2, OSX), late osteoblast markers (COL1A1), common osteoblast and adipocyte markers (ALP), and adipogenesis markers (C / EBPA) was analyzed by qPCR at each differentiation stage. First, hMSCs were isolated as MR1-B1 positive (+) and negative (-) using the MR1-B1 antibody as in Example 5-1 above, and differentiation into adipocytes was induced from the isolated MR1-B1 positive (+) and negative (-) hMSCs, respectively, as in Example 4-2. Total RNA was isolated from differentiated cells, and the expression of each marker in MR1-B1 positive (+) and MR1-B1 negative (-) cells was analyzed by qPCR, after which the expression ratios between the positive (+) and negative (-) groups were compared. As a result, there was no difference of more than 1.5 times between MR1-B1 positive (+) and negative (-) groups for osteoblast formation markers (RUNX2, OSX, COL1A1); however, in the case of ALP, a common osteoblast and adipocyte marker, it increased 4-fold during 14 days of differentiation and 7,838-fold during 21 days of differentiation in MR1-B1 negative (-) cells, and in the case of CEBPA, a late adipocyte marker, it also increased 5-fold during 14 days of differentiation and 4-fold during 21 days of differentiation in MR1-B1 negative (-) cells (see Fig. 13, Table 3, and Fig. 19A). These results indicate that MR1-B1 negative (-) cells isolated from hMSCs can be used as adipocyte differentiation markers (see Fig. 19A).

[0151] 5-3. Comparison of integrin αV expression induction during osteoblast differentiation in MR1-B1 negative and positive hMSCs.

[0152] When the distinguished hMSCs were differentiated into osteoblasts for 21 days as in Example 4-1 above, all osteoblast formation markers were progressively upregulated in MR1-B1 negative (-) hMSCs during osteoblast formation differentiation, and in the case of ALP, it was induced to be even 3 times higher in MR1-B1 negative (-) hMSCs than in MR1-B1 positive (+) hMSCs during osteoblast formation differentiation over 21 days (see Figs. 12C to 12G). Therefore, as in Example 1 above, changes in integrin αV expression between MR1-B1 positive (+) and negative (-) hMSCs were compared by flow cytometry. In MR1-B1 negative (-) hMSCs, integrin αV expression was significantly restored (approximately a 7-fold increase) during osteoblast formation differentiation on day 21 (see Figs. 13A and 13B). As shown in Fig. 12, the early and late osteoblast markers Runx2, ALP, OSX, and COL1A1 were also significantly increased during osteoblast differentiation on day 21 in MR1-B1-negative (-) hMSCs compared to day 0, indicating that increased integrin αV expression is closely associated with osteoblast induction. Consistent with these results, a significant amount of Alizarin Red S staining is observed in MR1-B1-negative (-) hMSCs during osteoblast differentiation on day 21 (see Fig. 12B). Taken together, these results suggest that integrin αV expression is induced during osteoblast differentiation even in MR1-B1-negative (-) hMSCs, indicating that integrin αV expression is a good indicator of OB differentiation.

[0154] 6. ER7-A7 Marker Comparison

[0155] 6-1. Comparison of markers during osteoblast differentiation in ER7-A7 positive and negative hMSCs.

[0156] The osteoblast potential of ER7-A7 positive (+) and negative (-) hMSCs was investigated following ER7-A7-based autologous cell sorting. Antibodies were biotinized using the DSB-X Biotin Labeling Kit (Thermo Fischer Scientific) according to the manufacturer's protocol. To separate hMSCs into ER7-A7 positive (+) and negative (-) groups, 5 million hMSC cells were reacted with 20 µg of biotinized ER7-A7 antibody at room temperature for 30 minutes while shaking. Cell sorting was performed using the Dynabeads FlowComp Flexi Kit (Thermo Fischer Scientific) according to the manufacturer's protocol. Unconjugated hMSCs were isolated and analyzed with Alexa488-conjugated mouse IgG (Thermo Fischer Scientific) and FACSCalibur to confirm successful sorting (Fig. 15A). Both sorted ER7-A7 positive (+) and negative (-) hMSCs were cultured in ODM for 21 days. As in Example 4-1, SB431542 was added to ODM after 7 days of osteoblastic differentiation. During the 21 days of osteoblastic differentiation, the expression levels of Runx2 and OSX in ER7-A7 positive (+) hMSCs were significantly upregulated by 1400-fold and 5600-fold, respectively, which are approximately 4-fold and 5-fold higher than in ER7-A7 negative (-) hMSCs (see Fig. 15B, Table 3, and Fig. 19B). The expression of the late OB marker COL1A1 was progressively upregulated by 5.1-fold at day 14 and 5.5-fold at day 21, and was 2-fold and 3-fold higher in ER7-A7-positive (+) hMSCs than in ER7-A7-negative (-) hMSCs, respectively (see Fig. 15D, Table 3, and Fig. 19B). The expression level of the common marker ALP was higher in ER7-A7-negative (-) hMSCs than in ER7-A7-positive (+) hMSCs, but there was no significant difference (Fig. 15E, Table 3, and Fig. 19B).The expression level of C / EBPA, a marker of adipogenesis, did not show significant differences during 14 days of differentiation, but increased 81-fold in ER7-A7 negative (-) hMSCs during 21 days of differentiation, which was more than 7-fold compared to ER7-A7 positive (+) hMSCs (Fig. 15F, Table 3, Fig. 19B). Therefore, it can be seen that while the expression levels of major osteoblast-forming transcription factors (Runx2, OSX, COL1A1) were upregulated in ER7-A7 positive (+) hMSCs, the expression level of the adipogenesis transcription factor C / EBPA was upregulated in ER7-A7 negative (-) hMSCs during osteoblastic differentiation of hMSCs. These results indicate that ER7-A7 positive (+) hMSCs possess greater osteoblast-forming ability than ER7-A7 negative (-) hMSCs, and that ER7-A7 negative (-) cells tend to differentiate into adipocytes.

[0158] 6-2. Comparison of markers during adipocyte differentiation in ER7-A7 positive and negative hMSCs.

[0159] When ER7-A7 positive (+) and negative (-) hMSCs isolated from hMSCs using an ER7-A7 antibody were differentiated into adipocytes for 0, 14, or 21 days, the expression of early osteoblast formation markers (RUNX2, OSX), late osteoblast markers (COL1A1), common osteoblast and adipocyte markers (ALP), and adipogenesis markers (C / EBPA) was analyzed by qPCR at each differentiation stage. First, hMSCs were isolated as ER7-A7 positive (+) and negative (-) using an ER7-A7 antibody as in Example 6-1 above, and the isolated ER7-A7 positive (+) and negative (-) hMSCs were each induced to differentiate into adipocytes as in Example 4-2 above. As a result, while there was no significant difference in OSX, an early osteoblast formation marker, at 21 days of differentiation, RUNX2 increased 552-fold in ER7-A7 negative (-) cells, which was more than 17 times higher than in positive (+) cells (see Figs. 16A, 16B, Table 3, and Fig. 19B). Additionally, COL1A1, a late osteoblast marker, also increased slightly by about 2-fold in negative (-) cells (see Fig. 16C, Table 3, and Fig. 19B). In the case of ALP, a common osteoblast and adipocyte marker, it increased 302-fold during 14 days of differentiation and 210,000-fold during 21 days of differentiation in ER7-A7 negative (-) cells, which is a 6-fold and 15-fold increase, respectively, compared to positive (+) cells (see Fig. 16D, Table 3, and Fig. 19B). In the case of CEBPA, a late adipocyte marker, it increased 39,000-fold during 14 days of differentiation and 3,000,000-fold during 21 days of differentiation in ER7-A7-negative (-) cells, showing that ER7-A7-negative (-) cells express CEBPA 247-fold and 5,725-fold more, respectively, than ER7-A7-positive (+) cells. These results suggest that ER7-A7-negative (-) cells in hMSCs are good markers for adipocytes and that ER7-A7-negative (-) cells isolated from hMSCs can be used for adipocyte differentiation (see Fig. 19B).

[0161] 7. Analysis of MR14-E5, ER7-A7, and MR1-B1 antibody genes and amino acids.

[0162] 7-1. MR14-E5 Gene Cloning and Amino Acid Sequencing.

[0163] 5 x 10 MR14-E5 cell clones, which are vigorously growing hybridoma cells 6After harvesting the dogs by centrifugation, total RNA was extracted using RNA iso plus reagent (TaKaRa, Otsu, Japan) according to the supplier's protocol. The amount of the obtained total RNA was quantified by measuring A260. cDNA was synthesized by preparing a reverse transcription polymerase chain reaction mixture using total RNA and Prime Script RT Master Mix (TaKaRa). To clone the antibody gene, known polymerase chain reaction primers were modified and used. For heavy chain cloning with synthesized cDNA, a polymerase chain reaction mixture was prepared by adding 10 pmole of oligonucleotides with the sequence 5'-GGA GTC GAC CTT GAC CAG GCA TCC TAG AGT CA- 3' (Sequence No. 55), which are polymerase chain reaction primers corresponding to the IgG2a constant region, and oligonucleotides with the sequences 5'MH1 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TC-3' (Sequence No. 56) and 5'MH2 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TCW GG-3' (Sequence No. 57), which are primers corresponding to the N-terminus of the heavy chain antibody variable region. For light chain cloning, the oligonucleotide 5'-ggt gtc gac GGA TAC AGT TGG TGC AGC ATC-3' (SEQ No. 58), which corresponds to the kappa chain constant region, and the primer 5'MK 5'-cgg aag ctt GAY ATT GTG MTS ACM CAR WCT MCA-3' (SEQ No. 59), which corresponds to the kappa chain variable region N-terminus, were used, respectively. For efficient cloning of polymerase chain reaction products, a SalI restriction site was conferred to the 3'-primer terminus for the light chain, and a HindIII restriction site was conferred to the 5'-primer terminus. For the heavy chain, EcoRI was conferred to the 5'-primer and a SalI restriction site to the 3'-primer terminus.After mixing the heavy chain and light chain reaction solutions, the DNA double helix was first unwound by reacting at 95°C for 5 minutes, followed by 30 cycles of 1 minute at 95°C, 1 minute at 47°C, and 1 minute at 72°C. As a result, amplified DNA was obtained at a position approximately 400 bp, which is estimated to be the length of the DNA fragment corresponding to the heavy chain constant region, and at a position approximately 390 bp, which is estimated to be the length of the DNA fragment corresponding to the light chain constant region. To clone the amplified MR14-E5 gene, the polymerase chain reaction products were first treated with EcoRI and SalI for the heavy chain and HindIII and SalI for the light chain, then developed on a 1.0% (w / v) agarose gel, and DNA corresponding to approximately 400 bp and 390 bp was isolated using the FavorPrep GEL™PCR Purification Kit (Favorgen, Taiwan). pBluescript KS+, to be used as a vector for cloning heavy chain genes, was treated with EcoRI and SalI, and pBluescript KS+, to be used as a vector for cloning light chain genes, was treated with HindIII and SalI and then isolated using the FavorPrep GEL™PCR Purification Kit. These two DNA sequences were ligated with T4 DNA ligase (New England Biolab, USA) and transformed into E. coli DH5α using the CaCl2 method. For the heavy chain, clones with DNA inserts of approximately 400 bp were selected, and for the light chain, E. coli clones with inserts of approximately 390 bp were selected. To analyze the DNA sequences of the antibody genes, the aforementioned clones were cultured overnight in 3 ml of LB medium containing 100 µg / ml ampicillin. Subsequently, plasmid DNA was isolated using the DNA-Spin plasmid mini prep kit (Intron, Korea), and the sequences of each DNA insert were confirmed via nucleotide sequencing (Bionics, Korea).After translating the nucleotide sequences of heavy and light chain DNA into amino acids, the antigen recognition determinants according to the antibody structure were organized using Kabat numbering and labeled as CDR1, 2, and 3 in the sequences. As a result of comparative analysis of the antibody sequences, the heavy chain belonged to subgroup IIB, and the light chain belonged to subgroup V (see Figures 19 and 20). From the analysis of these genes, it was confirmed that the heavy and light chain genes are functional.

[0165] 7-2. ER7-A7 Gene Cloning and Amino Acid Sequencing.

[0166] 5 x 10⁶ ER7-A7 cells, which are vigorously growing hybridoma cells 6After centrifuging and harvesting the samples, they were washed with cold PBS, and total RNA was extracted using RNA iso plus reagent (TaKaRa) according to the supplier's protocol. The amount of RNA was quantified by measuring the A260 of the obtained total RNA. 1 unit of DNase I (TaKaRa) was added per 1 μg of total RNA and incubated at 37°C for 30 minutes to remove residual DNA; subsequently, 1 μl of 50 mM EDTA was added and incubated at 85°C for 5 minutes to inactivate DNase I and denature the total RNA. A reverse transcription polymerase chain reaction (PCR) mixture was prepared using the total RNA and the Prime Script RT reagent Kit (TaKaRa), and cDNA was synthesized according to the supplier's protocol. To clone the antibody gene, known PCR primers were modified and used. For heavy chain cloning with synthesized cDNA, a polymerase chain reaction mixture was prepared by adding 25 pmole of oligonucleotide 5'-gga gtc gac ATA GAC AGA TGG GGG TGT CGT TTT GGC-3' (SEQ No. 60), which is a polymerase chain reaction primer corresponding to the IgG1 constant region, 25 pmole of oligonucleotide 5'MH1 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TC-3' (SEQ No. 56), which is a primer corresponding to the N-terminus of the heavy chain antibody variable region, and 25 pmole of oligonucleotide 5'MH2 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TCW GG-3' (SEQ No. 57). For light chain cloning, the oligonucleotide 5'-ggt gtc gac GGA TAC AGT TGG TGC AGC ATC-3' (SEQ No. 58), which is a primer corresponding to the kappa chain constant region, and the primer 5'MK 5'-cgg aag ctt GAY ATT GTG MTS ACM CAR WCT MCA-3' (SEQ No. 59), which is a primer corresponding to the kappa chain variable region N-terminus, were used, respectively.For efficient cloning of polymerase chain reaction products, EcoRI and SalI restriction enzyme sites were conferred to the 5'-primer end and the 3'-primer end, respectively, for the heavy chain. For the light chain, HindIII and SalI restriction enzyme sites were conferred to the 5'-primer end and the 3'-primer end, respectively. After mixing the polymerase chain primers for the heavy or light chain with 1 unit of i-pfu DNA Polymerase (iNtRON Biotechnology, Korea), the reaction was first carried out once at 95°C for 5 minutes, followed by 30 cycles of 1 minute at 95°C, 1 minute at 35°C, and 1 minute at 72°C. As a result, amplified DNA was obtained at a position approximately 400 bp, which is estimated to be the length of the DNA fragment corresponding to the heavy chain constant region, and at a position approximately 390 bp, which is estimated to be the length of the DNA fragment corresponding to the light chain constant region. To clone the amplified ER7-A7 gene, the polymerase chain reaction products were first treated with EcoRI and SalI for the heavy chain and with HindIII and SalI for the light chain. The mixtures were then developed on a 1.0% (w / v) agarose gel, and DNA corresponding to approximately 400 bp and 390 bp was isolated using the FavorPrep GEL™ PCR Purification Kit (Favorgen, Taiwan). pBluescript KS+, to be used as the vector for cloning the heavy chain gene, was treated with EcoRI and SalI, and pBluescript KS+, to be used as the vector for cloning the light chain gene, was treated with HindIII and SalI and isolated using the FavorPrep GEL™ PCR Purification Kit. These two DNA sequences were ligated with T4 DNA ligase (New England Biolab, USA) and transformed into E. coli DH5α using the CaCl2 method. For the heavy chain, clones with DNA inserts of approximately 400 bp were selected, and for the light chain, E. coli clones with insertions of approximately 390 bp were selected.To analyze the DNA sequences of the antibody genes, the aforementioned clones were cultured overnight in 3 ml of LB medium containing 100 µg / ml ampicillin. Subsequently, plasmid DNA was isolated using a DNA-Spin plasmid mini prep kit (Intron, Korea), and the sequences of each DNA insert were verified via nucleotide sequencing (Bionics, Korea). After translating the DNA sequences of the heavy and light chains into amino acids, the antigen recognition determinants according to the antibody structure were identified using Kabat numbering and labeled as CDR1, 2, and 3 in the sequences. Comparative analysis of the antibody sequences revealed that the heavy chain belonged to subgroup IIA, and the light chain belonged to subgroup V (see Figures 21 and 22). From the analysis of these genes, it was confirmed that the heavy and light chain genes are functional.

[0168] 7-3. MR1-B1 Gene Cloning and Amino Acid Sequencing.

[0169] 5 x 10 MR1-B1 cell clones, which are vigorously growing hybridoma cells 6After harvesting the dogs by centrifugation, total RNA was extracted using RNA iso plus reagent (TaKaRa) according to the supplier's protocol. The amount of the obtained total RNA was quantified by measuring A260. cDNA was synthesized by preparing a reverse transcription polymerase chain reaction mixture using total RNA and Prime Script RT Master Mix (TaKaRa). To clone the antibody gene, known polymerase chain reaction primers were modified and used. For heavy chain cloning with synthesized cDNA, a polymerase chain reaction mixture was prepared by adding 10 pmole of oligonucleotides with the sequence 5'-GGA GTC GAC CTT GAC CAG GCA TCC TAG AGT CA - 3' (SEQ No. 55), which are polymerase chain reaction primers corresponding to the IgG2a constant region, and oligonucleotides with the sequences 5'MH1 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TC-3' (SEQ No. 56) and 5'MH2- 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TCW GG-3' (SEQ No. 57), which are primers corresponding to the N-terminus of the heavy chain antibody variable region. For light chain cloning, the oligonucleotide 5'-ggt gtc gac GGA TAC AGT TGG TGC AGC ATC-3' (SEQ No. 58), which corresponds to the kappa chain constant region, and the primer 5'MK 5'-cgg aag ctt GAY ATT GTG MTS ACM CAR WCT MCA-3' (SEQ No. 59), which corresponds to the kappa chain variable region N-terminus, were used, respectively. For efficient cloning of polymerase chain reaction products, a SalI restriction site was conferred to the 3'-primer end for the light chain, and a HindIII restriction site was conferred to the 5'-primer. For the heavy chain, an EcoRI restriction site was conferred to the 5'-primer, and a SalI restriction site was conferred to the 3'-primer.After mixing the heavy chain and light chain reaction solutions, the DNA double helix was first unwound by reacting at 95°C for 5 minutes, followed by 30 cycles of 1 minute at 95°C, 1 minute at 47°C, and 1 minute at 72°C. As a result, amplified DNA was obtained at a position approximately 400 bp, which is estimated to be the length of the DNA fragment corresponding to the heavy chain constant region, and at a position approximately 390 bp, which is estimated to be the length of the DNA fragment corresponding to the light chain constant region. To clone the amplified MR1-B1 gene, the polymerase chain reaction products were first treated with EcoRI and SalI for the heavy chain and with HindIII and SalI for the light chain, then developed on a 1.0% (w / v) agarose gel, and DNA corresponding to approximately 400 bp and 390 bp was isolated using the FavorPrep GEL™PCR Purification Kit (Favorgen, Taiwan). pBluescript KS+, to be used as a vector for cloning heavy chain genes, was treated with EcoRI and SalI, and pBluescript KS+, to be used as a vector for cloning light chain genes, was treated with HindIII and SalI and then isolated using the FavorPrep GEL™PCR Purification Kit. These two DNA sequences were ligated with T4 DNA ligase (New England Biolab, USA) and transformed into E. coli DH5α using the CaCl2 method. For the heavy chain, clones with DNA inserts of approximately 400 bp were selected, and for the light chain, E. coli clones with inserts of approximately 390 bp were selected. To analyze the DNA sequences of the antibody genes, the aforementioned clones were cultured overnight in 3 ml of LB medium containing 100 µg / ml ampicillin. Subsequently, plasmid DNA was isolated using the DNA-Spin plasmid mini prep kit (Intron, Korea), and the sequences of each DNA insert were confirmed via nucleotide sequencing (Bionics, Korea).After translating the nucleotide sequences of heavy and light chain DNA into amino acids, the antigen recognition determinants according to the antibody structure were organized using Kabat numbering and labeled as CDR1, 2, and 3 in the sequences. Comparative analysis of the antibody sequences revealed that the heavy chain belonged to subgroup IIB and the light chain belonged to subgroup V (see Figures 23 and 24). From the analysis of these genes, it was confirmed that the heavy and light chain genes are functional.

Claims

Claim 1 A monoclonal antibody comprising: a heavy chain variable region comprising CDR-H1 with the amino acid sequence of SEQ ID NO. 1, CDR-H2 with the amino acid sequence of SEQ ID NO. 2, and CDR-H3 with the amino acid sequence of SEQ ID NO. 3; and a light chain variable region comprising CDR-L1 with the amino acid sequence of SEQ ID NO. 4, CDR-L2 with the amino acid sequence of SEQ ID NO. 5, and CDR-L3 with the amino acid sequence of SEQ ID NO.

6. Claim 2 A composition for selecting mesenchymal stem cells having osteocytic differentiation ability comprising the monoclonal antibody of claim 1. Claim 3 A kit for screening mesenchymal stem cells having osteocytic differentiation ability comprising the composition of claim 2. Claim 4 A method for selecting mesenchymal stem cells having osteocytic differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of claim 2. Claim 5 A method for selecting mesenchymal stem cells having osteocytic differentiation ability according to claim 4, further comprising the step of selecting cells among the sample that bind to the antibody as cells having osteocytic differentiation ability. Claim 6 A composition for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the monoclonal antibody of claim 1. Claim 7 A kit for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the composition of claim 6. Claim 8 A method for selecting mesenchymal stem cells having adipocyte differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of claim 6. Claim 9 A method for selecting mesenchymal stem cells having adipocyte differentiation ability according to claim 8, further comprising the step of selecting cells among the sample that do not bind to the antibody as cells having adipocyte differentiation ability. Claim 10 A monoclonal antibody comprising: a heavy chain variable region comprising CDR-H1 with the amino acid sequence of SEQ ID NO. 7, CDR-H2 with the amino acid sequence of SEQ ID NO. 8, and CDR-H3 with the amino acid sequence of SEQ ID NO. 9; and a light chain variable region comprising CDR-L1 with the amino acid sequence of SEQ ID NO. 10, CDR-L2 with the amino acid sequence of SEQ ID NO. 11, and CDR-L3 with the amino acid sequence of SEQ ID NO.

12. Claim 11 A composition for selecting integrin α2-expressing mesenchymal stem cells comprising the monoclonal antibody of claim 10. Claim 12 A kit for screening integrin α2-expressing mesenchymal stem cells comprising the composition of claim 11. Claim 13 A method for selecting integrin α2-expressing mesenchymal stem cells, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of claim 11. Claim 14 A method for selecting integrin α2-expressing mesenchymal stem cells according to claim 13, further comprising the step of selecting cells among the samples that bind to the antibody as integrin α2-expressing mesenchymal stem cells. Claim 15 A monoclonal antibody comprising: a heavy chain variable region comprising CDR-H1 with the amino acid sequence of SEQ ID NO. 13, CDR-H2 with the amino acid sequence of SEQ ID NO. 14, and CDR-H3 with the amino acid sequence of SEQ ID NO. 15; and a light chain variable region comprising CDR-L1 with the amino acid sequence of SEQ ID NO. 16, CDR-L2 with the amino acid sequence of SEQ ID NO. 17, and CDR-L3 with the amino acid sequence of SEQ ID NO.

18. Claim 16 A composition for selecting mesenchymal stem cells having osteocytic differentiation ability comprising the monoclonal antibody of claim 15. Claim 17 A kit for screening mesenchymal stem cells having osteocytic differentiation ability comprising the composition of claim 16. Claim 18 A method for selecting mesenchymal stem cells having osteocytic differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of claim 16. Claim 19 A method for selecting mesenchymal stem cells having osteocytic differentiation ability according to claim 18, further comprising the step of selecting cells among the sample that bind to the antibody as cells having osteocytic differentiation ability. Claim 20 A composition for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the monoclonal antibody of claim 15. Claim 21 A kit for selecting mesenchymal stem cells having adipocyte differentiation ability comprising the composition of claim 20. Claim 22 A method for selecting mesenchymal stem cells having adipocyte differentiation ability, comprising the step of treating a sample containing mesenchymal stem cells isolated from an individual with the composition of claim 20. Claim 23 A method for selecting mesenchymal stem cells having adipocyte differentiation ability according to claim 22, further comprising the step of selecting cells among the sample that do not bind to the antibody as cells having adipocyte differentiation ability.

Citation Information

Patent Citations

  • Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and their use

    JP2017525670A

  • Monoclonal antibody 297-D4 specific to undifferentiated human embryonic stem cell

    KR1020120127774A